

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 October 2001 (25.10.2001)

PCT

(10) International Publication Number
WO 01/78651 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number: **PCT/US01/11865**
- (22) International Filing Date: 12 April 2001 (12.04.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/548,135 12 April 2000 (12.04.2000) **US**
- (71) Applicant: **CELL PATHWAYS, INC.** [US/US]; 702 Electronic Drive, Horsham, PA 19044 (US).
- (72) Inventors: **PAMUKCU, Rifat**; 2 Pump House Drive, Spring House, PA 19477 (US). **LOBACKI, Joseph**; 1263 Turnbury Lane, North Wales, PA 19454 (US).
- (74) Agent: **STEVENSON, Robert, W.**; Cell Pathways, Inc., 702 Electronic Drive, Horsham, PA 19044 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/78651 A2

(54) Title: METHOD FOR TREATING A PATIENT WITH NEOPLASIA BY TREATMENT WITH A TOPOISOMERASE I INHIBITOR

(57) Abstract: This invention provides a method for treating a patient with neoplasia by an adjuvant therapy that includes treatment with a topoisomerase I inhibitor.

**METHOD FOR TREATING A PATIENT WITH NEOPLASIA BY
TREATMENT WITH A TOPOISOMERASE I INHIBITOR**

BACKGROUND OF THE INVENTION

5 Virtually all of the many antineoplastic drugs that are currently used in the treatment of cancer have very serious and harmful side effects. This is because cancer is generally treated with medications that interfere with the growth of rapidly dividing cells. Such medications can inhibit the growth of the cancer cells, but they almost always also inhibit the growth of normal cells that divide rapidly in the body. Some of the normal tissues that divide
10 very rapidly include bone marrow (which produces blood cells), hair follicles, and intestinal epithelium. The usefulness of virtually all antineoplastic drugs is severely limited by the damage they cause to these normal tissues.

 This invention relates to methods for treating neoplasia using both an antineoplastic topoisomerase I inhibitor (a common chemotherapeutic) and a cyclic GMP (cGMP)-specific
15 phosphodiesterase (PDE) inhibitor to reduce the side effects or increase the efficacy of topoisomerase I inhibitor treatment.

 Examples of topoisomerase I inhibitor class compounds are camptothecins (e.g., Rubitecan, irinotecan hydrochloride and topotecan hydrochloride). Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by
20 inducing reversible single-strand breaks. Irinotecan (and its active metabolite SN-38) and topotecan bind to the topoisomerase I-DNA complex and prevent re-ligation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan and topotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either
25 irinotecan (or SN-38) or topotecan. Mammalian cells cannot efficiently repair these double-strand breaks.

 Camptothecins can induce both early and late forms of diarrhea that appear to be mediated by different mechanisms. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion of irinotecan) may be accompanied by cholinergic
30 symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Late diarrhea (generally

occurring more than 24 hours after administration of irinotecan) can be prolonged, may lead to dehydration and electrolyte imbalance, and can be life threatening. section).

Administration of irinotecan, for example, should be interrupted and subsequent doses reduced if severe diarrhea occurs

5 Deaths due to sepsis following severe myelosuppression have been reported in patients treated with irinotecan and topotecan. In fact, it is the dose-limiting toxicity of topotecan.

The adverse effects of camptothecins, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.

10 The usual recommended starting dose of irinotecan injection is 125 mg/m^2 . In patients with a combined history of prior pelvic/abdominal irradiation and modestly elevated serum total bilirubin levels (1.0 to 2.0 mg/dL) prior to treatment with irinotecan, there may be a substantially increased likelihood of grade 3 or 4 neutropenia. Consideration is often given to starting irinotecan at a lower dose (e.g., 100 mg/m^2) in such patients.

15 After initiation of treatment with irinotecan, patients should be carefully monitored for toxicity. Subsequent doses should be adjusted to as high as 150 mg/m^2 or to as low as 50 mg/m^2 in 25 to 50 mg/m^2 increments depending upon individual patient tolerance of treatment.

Alternatively, irinotecan can be administered on a once-every-3-week dosage
20 schedule. The usual recommended starting dose of CAMPTOSAR Injection for the once-every-3-week dosage schedule is 350 mg/m^2 . For patients who are 70 years and older, or who have received prior pelvic/abdominal radiotherapy, or who have a performance status of 2 the recommended starting dose is 300 mg/m^2 . After initiation of treatment with irinotecan, patients should be carefully monitored for toxicity. Subsequent doses should be adjusted to
25 as low as 200 mg/m^2 in 50-mg/m^2 increments depending upon individual patient tolerance of treatment

Topotecan have been evaluated in cancer patients following doses of 0.5 to 1.5 mg/m^2 administered as a 30-minute infusion.

Rubitecan (from Supergen) also is an oral topoisomerase I inhibitor in the
30 camptothecin class. It has been studied at doses of about $1.5 \text{ mg/m}^2/\text{day}$ for 5 days/week for 8 weeks.

This invention also relates to methods for causing the use of an anti-neoplastic cGMP-phosphodiesterase inhibitor in combination with a topoisomerase I inhibitor to be used for the treatment and prevention of pre-cancerous and cancerous lesions in mammals.

When a novel mechanism of action is announced to the world, competitors, even
5 those with compounds that may act against secondary targets (e.g., sulindac which hits COX targets), can gain at the expense of the developer from suggesting to the medical community that their compounds act wholly or partially through the same novel mechanism. The advantages of such activities to such competitors is manifestly apparent to those skilled in the art of managing the business of pharmaceutical development.

10

SUMMARY OF THE INVENTION

This invention relates to an improved method of neoplasia therapy that involves treating a patient with both a topoisomerase I inhibitor and a cyclic GMP-specific phosphodiesterase (PDE) inhibitor. The specific PDE inhibitors useful for this invention are
15 compounds that inhibit both PDE5 and the types of PDE2 described below. The novel form of PDE2 disclosed herein is fully described by Liu, et al., in the copending U.S. Patent Application Serial No. 09/173,375, A Novel Cyclic GMP-Specific Phosphodiesterase And Methods For Using Same In Pharmaceutical Screening For Identifying Compounds For Inhibition Of Neoplastic Lesions. (For general PDE background, see, Beavo, J. A. (1995)
20 Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiological Reviews 75:725-747; web site <<http://weber.u.washington.edu/~pde/pde.html>> (Nov. 1998)).

In this invention, the cGMP-specific PDE inhibitor can be used in combination with a topoisomerase I inhibitor in two ways. The first is a lower dosage methodology in which the
25 traditionally recommended dose range of the topoisomerase I inhibitor is decreased while its therapeutic effects are maintained and its side effects are attenuated. The second is a higher dosage methodology that utilizes the traditionally recommended dose range for the topoisomerase I inhibitor and improves its activity without increasing its side effects. With each methodology, the topoisomerase I inhibitor is administered simultaneously with or in
30 succession with an appropriate cGMP-specific PDE inhibitor.

This invention also relates to packaged pharmaceutical compositions that are provided together with written materials describing the use of a cGMP-specific PDE inhibitor in combination with a topoisomerase I inhibitor for the treatment of cancer and precancerous lesions.

5

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graph of the cGMP activities of the cGMP phosphodiesterases obtained from SW480 neoplastic cells, as assayed from the eluent from a DEAE-Trisacryl M column.

Figure 2 is a graph of cGMP activities of the reloaded cGMP phosphodiesterases
10 obtained from SW480 neoplastic cells, as assayed from the eluent from a DEAE-Trisacryl M column.

Figure 3 is a graph of the kinetic behavior of the novel PDE of this invention.

Figure 4 illustrates the effect of the sulfide derivative of sulindac and the sulfone derivative of sulindac (a.k.a. exisulind) on purified cyclooxygenase activity.

15 Figure 5 illustrates the effects of test compounds B and E on COX inhibition.

Figure 6 illustrates the inhibitory effects of sulindac sulfide and exisulind on PDE4 and PDE5 purified from cultured tumor cells.

Figure 7 illustrates the effects of sulindac sulfide on cyclic nucleotide levels in HT-29 cells.

20 Figure 8 illustrates the phosphodiesterase inhibitory activity of compound B.

Figure 9 illustrates the phosphodiesterase inhibitory activity of compound E.

Figure 10 illustrates the effects of sulindac sulfide and exisulind on apoptosis and necrosis of HT-29 cells.

Figure 11 illustrates the effects of sulindac sulfide and exisulind on HT-29 cell growth
25 inhibition and apoptosis induction as determined by DNA fragmentation.

Figure 12 illustrates the apoptosis-inducing properties of compound E.

Figure 13 illustrates the apoptosis-inducing properties of compound B.

Figure 14 illustrates the effects of sulindac sulfide and exisulind on tumor cell growth.

Figure 15 illustrates the growth inhibitory and apoptosis-inducing activity of sulindac
30 sulfide and control (DMSO).

Figure 16 illustrates the growth inhibitory activity of compound E.

Figure 17 illustrates the inhibition of pre-malignant, neoplastic lesions in mouse mammary gland organ culture by sulindac metabolites.

Figure 18 A is a SDS protein gel of SW480 cell lysates from drug-treated cell lysates
5 in the absence of added cGMP, where cells were treated in culture for 48 hours with DMSO (0.03%, lanes 1 and 2), exisulind (200, 400 and 600 μ M; lanes 3, 4, 5) and E4021 (0.1, 1 and 10 μ M, lanes 6, 7, 8).

Figure 18 B is a SDS (X-ray film exposure) gel PKG assay of SW480 cell lysates from drug-treated cell lysates in the presence of added cGMP, where cells were treated in
10 culture for 48 hours with DMSO (0.03%, lanes 1 and 2), exisulind (200, 400 and 600 μ M; lanes 3, 4, 5) and E4021 (0.1, 1 and 10 μ M, lanes 6, 7, 8).

Figure 19 is a bar graph of the results of Western blot experiments of the effects of exisulind on β -catenin and PKG levels in neoplastic cells relative to control.

Figure 20 is a graph of the cGMP activities of the cGMP phosphodiesterases obtained
15 from HTB-26 neoplastic cells, as assayed from the eluent from a DEAE-Trisacryl M column.

Figure 21 is a graph of the cGMP activities of the cGMP phosphodiesterases obtained from HTB-26 neoplastic cells, as assayed from the eluent from a DEAE-Trisacryl M column with low and high substrate concentration.

Figure 22 is a graph of the cGMP activities of the cGMP phosphodiesterases obtained
20 from LnCAP neoplastic cells, as assayed from the eluent from a DEAE-Trisacryl M column.

Figure 23 is a graph of the cGMP activities of the cGMP phosphodiesterases obtained from LnCAP neoplastic cells, as assayed from the eluent from a DEAE-Trisacryl M column with low and high substrate concentration.

Figure 24 is a bar graph illustrating the specificity binding of the non-catalytic cGMP
25 binding sites of PDE5 for cyclic nucleotide analogs and selected PDE5 inhibitors.

Figure 25 is a graph of the cGMP activities of the cGMP phosphodiesterases obtained from SW480 neoplastic cells, as assayed from the eluent from a DEAE-Trisacryl M column using ethylene glycol in the buffer.

Figure 26 is a graph of the cGMP activities of the cGMP phosphodiesterases obtained
30 from SW480 neoplastic cells grown in roller bottles, as assayed from the eluent from a DEAE-Trisacryl M column.

Figure 27A shows a time-dependent increase in the amount of histone-associated fragmented DNA in LNCaP cell cultures following treatment with 50 μ M Compound I.

Figure 27B shows the course of treatment of PrEC prostate cells with Compound I (50 μ M) that did not affect DNA fragmentation for up to 4 days of treatment.

5 Figure 28 is a bar graph illustrating the effect of Compound I with various concentrations of Camptosar (irinotecan hydrochloride) on Calu-6 adenocarcinoma cell line where the cells were exposed to both agents for one hour.

Figure 29 is a bar graph illustrating the effect of Compound I with various concentrations of Camptosar (irinotecan hydrochloride) on Calu-6 adenocarcinoma cell line
10 where the cells were exposed to topoisomerase I inhibitor for one hour and Compound I continuously.

Figure 30 is a bar graph illustrating the effect of Compound I with various concentrations of Camptosar (irinotecan hydrochloride) on H460 lung cancer cell line where the cells were exposed to both agents for one hour.

15 Figure 31 is a bar graph illustrating the effect of Compound I with various concentrations of Camptosar (irinotecan hydrochloride) on H460 lung cancer cell line where the cells were exposed to topoisomerase I inhibitor for one hour and Compound I continuously.

Figure 32 is a bar graph illustrating the effect of exisulind with various concentrations
20 of Camptosar (irinotecan hydrochloride) on Calu-6 adenocarcinoma cell line where the cells were exposed to both agents for one hour.

Figure 33 is a bar graph illustrating the effect of exisulind with various concentrations of Camptosar (irinotecan hydrochloride) on Calu-6 adenocarcinoma cell line where the cells were exposed to topoisomerase I inhibitor for one hour and exisulind continuously.

25 Figure 34 is a bar graph illustrating the effect of exisulind with various concentrations of Navelbine on H460 lung cancer cell line where the cells were exposed to both agents for one hour.

Figure 35 is a bar graph illustrating the effect of exisulind with various concentrations of Navelbine on H460 lung cancer cell line where the cells were exposed to topoisomerase I
30 inhibitor for one hour and exisulind continuously.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

As discussed in greater detail below, the inhibition of cGMP-specific PDEs can induce apoptosis in neoplastic cells. Topoisomerase I inhibitor are currently used to treat neoplasias, particularly ovarian, pancreatic, lung, lymph, colon and gastric cancers. The combination of these two types of therapies can produce an effect that neither can produce individually.

I. IN GENERAL

As explained above, this invention among other things is a method of causing the use of a particular class of anti-neoplastic cGMP PDE inhibitor that acts through the pathways described herein, in conjunction with a topoisomerase I inhibitor. This method includes obtaining a pharmaceutical composition that includes such a cGMP PDE inhibitor having one or more of the attributes set forth herein, informing physicians and patients about those attributes, providing said pharmaceutical composition to physicians and patients in need of treatment; and causing a patient to receive said pharmaceutical composition in conjunction with topoisomerase I inhibitor therapy. This invention also involves obtaining a pharmaceutical composition that includes a topoisomerase I inhibitor, providing said pharmaceutical composition to physicians and patients in need of treatment; and causing a patient to receive said pharmaceutical composition in conjunction with an anti-neoplastic cGMP PDE inhibitor.

By "informing the physician and patient," we mean the entire range of direct or indirect medical educational efforts whereby pharmaceuticals are (in effect) marketed to doctors, and thereby their patients. By way of example only, one way is for the manufacturer to conduct the required mechanistic studies (of the type described below) to ascertain whether his compound has the attributes set forth herein, and then publishing the results of those studies in one or more publications or including such information in a package insert that accompanies the pharmaceutical. Alternatively, pharmaceutical companies can sponsor or initiate such mechanistic studies to be performed by third parties, and the results of those third party studies are then published.

Those reports are then used by the pharmaceutical company in its medical education and marketing efforts. For example, copies of published reports can be distributed by the company or its agents directly to doctors at conventions or in their offices in an effort to convince the physician that the drug indeed has the attributes that warrant use. Alternatively, 5 those reports can be posted on the Internet directly or indirectly by the company or its agents. Also, the company can arrange for (or have arranged for it) continuing medical education carriers to organize events where doctors are provided such data. These and similar efforts are used by pharmaceutical companies to inform physicians and thereby the patients so that the prescribers and users of such pharmaceuticals come to understand that the drug sold by 10 the manufacturer has one or more of the attributes set forth herein.

By "packaged pharmaceutical," we mean the drug (either the anti-neoplastic cGMP PDE inhibitor or the topoisomerase I inhibitor) as formulated in its form to be administered to the patient) packaged in a bottle or blister card (that may or may not then be boxed with other bottles or blister cards), IV bag, aerosol inhaler, syringe, ointment tube, or the like. The 15 "written material" is that material describing said compound characterized as having one or more of the attributes set forth herein, and typically containing directions for use in accordance with the teachings of this invention. One non-limiting type of written material is a package insert, but brochures and the like represent other types. Written material also includes (but is not limited to) those materials in electronic form.

20 The packaging can carry such written material by having the written material affixed (releasably or otherwise) to the outside of the container, or provided inside the container itself (e.g., in the case of tableted drug, an insert inside the bottle containing the tablets). Alternatively, if the bottled pharmaceutical is packaged in multiple bottles in shipping containers (e.g., boxes), one or more copies of the written material can be placed in the outer 25 box. If the bottled pharmaceutical is boxed in an individual box, the written material can be inside or on the box.

II. THE NOVEL CGMP-SPECIFIC PHOSPHODIESTERASE AND PDE2 FROM NEOPLASTIC CELLS

A. In General

One aspect of the pathway involved in this invention is the inhibition of a PDE2 that
5 exhibits a novel conformation and a conventional one, depending on the circumstances. In
addition to inhibiting PDE5, pro-apoptotic PDE5 inhibitors inhibit this PDE2-like enzyme,
whereas PDE5 inhibitors that do not induce apoptosis have not been found to inhibit this
PDE2-like enzyme.

B. The Isolation Of The Novel PDE Conformation

10 In one aspect of the pathway described herein, an isolated cGMP-specific
phosphodiesterase (which appears to be a novel conformation of PDE2) was first prepared
from the human carcinoma cell line commonly referred to as SW480 available from the
American Tissue Type Collection in Rockville, Maryland, U.S.A. SW480 is a human colon
cancer cell line that originated from moderately differentiated epithelial adenocarcinoma. As
15 discussed below, a similar conformation has also been isolated from neoplasias of the breast
(i.e., HTB-26 cell line) and prostate (i.e., LNCAP cell line).

By "isolated" we mean (as is understood in the art) not only isolated from neoplastic
cells, but also made by recombinant methods (e.g., expressed in a bacterial or other non-
human host vector cell lines). However, we presently believe isolation from the human
20 neoplastic cell line is preferable since we believe that the target protein so isolated has a
structure (i.e., a conformation or topography) that is closer to, if not identical with, one of the
native conformations in the neoplastic cell. This conformation assists in the selection of anti-
neoplastic compounds that will inhibit the target enzyme(s) *in vivo*.

The novel PDE activity was first found in SW480 colon cancer cell lines. To isolate
25 the novel phosphodiesterase from SW480, approximately four hundred million SW480 cells
were grown to confluence in and were scraped from 150 cm² tissue culture dishes after two
washes with 10 mL cold PBS and pelleted by centrifugation. The cells were re-suspended in
homogenization buffer (20 mL TMPI-EDTA-Triton pH 7.4: 20 mM Tris-HOAc, 5 mM
MgAc₂, 0.1 mM EDTA, 0.8% Triton-100, 10µM benzamidine, 10µM TLCK, 2000 U/mL
30 aprotinin, 2 µM leupeptin, 2 µM pepstatin A) and homogenized on an ice bath using a

polytron tissumizer (three times, 20 seconds/pulse). The homogenized material was centrifuged at 105,000 g for 60 minutes at 4°C in a Beckman L8 ultracentrifuge, and the supernatant was diluted with TMPI-EDTA (60 mL) and applied to a 10-milliliter DEAE-Trisacryl M column pre-equilibrated with TMPI-EDTA buffer. The loaded column was washed with 60 mL of TM-EDTA, and PDE activities were eluted with a 120 mL linear gradient of NaOAC (0-0.5 M) in TM-EDTA, at a flow rate of 0.95 mL/minute, 1.4 mL/fraction. Eighty fractions were collected and assayed for cGMP hydrolysis immediately (i.e. within minutes). Figure 1. shows the column's elution profile, revealing two initial peaks of cGMP PDE activity, Peaks A and B, which were eluted by 40-50 mM and 70-80 mM NaOAC, respectively. As explained below, Peak A is PDE5, whereas Peak B is a novel cGMP-specific phosphodiesterase activity.

Cyclic nucleotide PDE activity of each fraction was determined using the modified two-step radio-isotopic method of Thompson et al. (Thompson W.J., et al., Adv. Cyclic Nucleotide Res. 10: 69-92, 1979), as further described below. The reaction was in 400 µl containing Tris-HCl (40mM; pH 8.0), MgCl₂ (5mM), 2-mercaptoethanol (4 mM), bovine serum albumin (30 µg), cGMP (0.25µM-5µM) with constant tritiated substrate (200,000 cpm). The incubation time was adjusted to give less than 15% hydrolysis. The mixture was incubated at 30°C followed by boiling for 45 seconds to stop the reaction. Then, the mixture was cooled, snake venom (50µg) added, and the mixture was incubated at 30°C for 10 minutes. MeOH (1 mL) was added to stop the reaction, and the mixture was transferred to an anion-exchange column (Dowex 1-X8, 0.25 mL resin). The eluent was combined with a second mL of MeOH, applied to the resin, and after adding 6 mL scintillation fluid, tritium activity was measured using a Beckman LS 6500 for one minute.

To fractionate the cGMP hydrolytic activities of Peaks A and B further, fractions 15 to 30 of the original 80 were reloaded onto the DEAE-Trisacryl M column and eluted with a linear gradient of NaOAC (0-0.5 M) in TM-EDTA. Fractions were again immediately assayed for cGMP hydrolysis (using the procedure described above with 0.2, 2, 5µM substrate), the results of which are graphically presented in Figure 2. One observation about Peak B illustrated in Figure 2 is that increasing substrate concentration of cGMP dramatically enhanced activity when contrasted to Peak A. While this observation is consistent with its being a PDE2, the fact that the enzyme characterized in Figure 2 is cGMP-specific (see

below) suggests that it has a novel conformation compared to the classic PDE2 reported in the literature. Peak A activity shows apparent substrate saturation of high affinity catalytic sites.

C. The Isolation of Classic PDE2 From SW480

5 Two methods were found that allowed "Peak B" to be isolated from SW480 so that the enzyme had the classical PDE2 activity (i.e. was not cGMP-specific, but was cGMP stimulated). The first method involved growing the SW480 in 850 cm² Corning roller bottles instead of 150 cm² tissue culture flasks. SW480 were grown in roller bottles at 0.5 rpm with each bottle containing 200 mL of RPMI 1640, 2 mM glutamine, and 25 mM HEPES. Cells
10 were harvested by the following procedure.

PBS media was warmed to 37°C for at least 15 minutes. 200 mL of 5% FBS/RPMI 1640 complete media was prepared and 5 mL of glutamine was added. 5 mL of antibiotic/antimycotic was also added.

70 mL of the PBS solution was added to 10 mL of 4X Pancreatin. The mixture was
15 maintained at room temperature. The media was removed and the flask was rinsed with 4 mL of PBS being sure the bottom of the flask was covered. All solution was removed with a pipet. 4 mL of diluted Pancreatin was added to the flask, and the flask was swished to cover its bottom. The flask was incubated at 37°C for 8-10 minutes. After the incubation, the flask was quickly checked under an inverted microscope to make sure all cells were rounded. The
20 flask was hit carefully on its side several times to help detach cells. 10 mL of cold complete media was added to the flask to stop the Pancreatin proteolysis. The solution was swirled over the bottom to collect the cells. The media was removed using a 25 mL pipet, and the cells placed in 50 mL centrifuge tubes on ice. The tubes were spun at 1000 rpm at 4°C for 5 minutes in a clinical centrifuge to pellet cells. The supernatant was poured off and each
25 pellet frozen on liquid nitrogen for 15 seconds. The harvested cells can be stored in a -70°C freezer.

The PDEs from the harvested SW480 cells were isolated using an FPLC procedure. A Pharmacia AKTA FPLC was used to control sample loading and elution on an 18 mL DEAE TrisAcryl M column. About 600 million cells of SW480 were used for the profiles.
30 After re-suspending cells in homogenization buffer (20 mL TMPI-EDTA-Triton pH 7.4: 20

mM Tris-HOAc, 5 mM MgAc₂, 0.1 mM EDTA, 0.8% Triton-100, 10μM benzamidine, 10μM TLCK, 2000 U/mL aprotinin, 2 μM leupeptin, 2 μM pepstatin A), samples were manually homogenized. FPLC buffer A was 8 mM TRIS-acetate, 5 mM Mg acetate, 0.1 mM EDTA, pH 7.5 and buffer B was 8 mM TRIS-acetate, 5 mM Mg acetate, 0.1 mM EDTA, 1 M Na acetate, pH 7.5. Supernatants were loaded onto the column at 1 mL per minute, followed by a wash with 60 mL buffer A at 1 mL per minute. A gradient was run from 0-15% buffer B in 60 mL, 15-50% buffer B in 60 mL, and 50-100% buffer B in 16 mL. During the gradient, 1.5 mL fractions were collected.

The profile obtained was similar (Figure 26) to the profile for the novel PDE activity (see, e.g., Figure 1) obtained above, except that Peak B isolated in this manner showed cAMP hydrolytic activity at 0.25 μM substrate that could be activated 2-3 fold by 5 μM cGMP.

A second method used to isolate classic PDE2 from SW480 was done using a non-FPLC DEAE column procedure described above (see Section IIB) with the modification that the buffers contained 30% ethylene glycol, 10 mM TLCK and 3.6 mM β-mercaptoethanol.

The addition of these reagents to the buffers causes a shift in the elution profile (see Figure 25) from low to high sodium acetate so that Peak A moves from 40 to 150 mM, Peak B from 75 to 280 mM and Peak C from 200 to 500 mM Na acetate (see Figure 25). Peak B in Figure 25 was assayed with 2 μM cAMP substrate and showed a two-fold activation by 5 μM cGMP (see Figure 26). The selective PDE2 inhibitor EHNA inhibited 2 μM cGMP PDE activity in this Peak B with an IC₅₀ of 1.6 μM and inhibited 2.0 μM cAMP PDE activity in Peak B with an IC₅₀ of 3.8 μM (and IC₅₀ of 2.5 μM with addition of 10 μM rolipram).

D. cGMP-Specificity of PDE Peak A and The Novel Peak B Activity

Each fraction from the DEAE column from Section IIB was also assayed for cGMP-hydrolysis activity (0.25μM cGMP) in the presence or absence of Ca⁺⁺, or Ca⁺⁺-CaM and/or EGTA and for cAMP (0.25μM cAMP) hydrolysis activity in the presence or absence of 5μM cGMP. Neither PDE Peak A and Peak B (fractions 5-22; see Figure 1) hydrolyzed cAMP significantly, establishing that neither had the activity of a classic cAMP-hydrolyzing family of PDE (i.e. a PDE 1, 2, 3).

Ca⁺⁺ (with or without calmodulin) failed to activate either cAMP or cGMP hydrolysis activity of either Peak A or B, and cGMP failed to activate or inhibit cAMP hydrolysis. Such

results establish that Peaks A and B constitute cGMP-specific PDE activities but not classic or previously known PDE1, PDE2, PDE3 or PDE4 activities.

For the novel PDE Peak B, as discussed below, cyclic GMP activated the cGMP hydrolytic activity of the enzyme, but did not activate any cAMP hydrolytic activity (in contrast with the Peak B from Section IIC above). This reveals that the novel PDE Peak B -- the novel phosphodiesterase of this invention -- is not a cGMP-stimulated cAMP hydrolysis ("cGS") or among the classic or previously known PDE2 family activities because the known isoforms of PDE2 hydrolyze both cGMP and cAMP.

E. Peak A Is A Classic PDE5, But The Novel Peak B--A New cGMP-Specific PDE--Is Not

To characterize any PDE isoform, kinetic behavior and substrate preference should be assessed.

Peak A showed typical "PDE5" characteristics. For example, the K_m of the enzyme for cGMP was 1.07 μ M, and V_{max} was 0.16 nmol/min/mg. In addition, as discussed below, zaprinast ($IC_{50}=1.37\mu$ M) and E4021 ($IC_{50}=3$ nM) and sildenafil inhibited activity of Peak A. Further, zaprinast showed inhibition for cGMP hydrolysis activity of Peak A, consistent with results reported in the literature.

PDE Peak B from Section IIB showed considerably different kinetic properties as compared to PDE Peak A. For example, in Eadie-Hofstee plots of Peak A, cyclic GMP hydrolysis shows single line with negative slope with increasing substrate concentrations, indicative of Michaelis-Menten kinetic behavior. Peak B, however, shows the novel property for cGMP hydrolysis in the absence of cAMP of a decreasing (apparent $K_m = 8.4$), then increasing slope ($K_m < 1$) of Eadie-Hofstee plots with increasing cGMP substrate (see, Figure 3). Thus, this establishes Peak B's submicromolar affinity for cGMP (i.e., where $K_m < 1$).

Consistent with the kinetic studies (i.e., Figure 3) and positive-cooperative kinetic behavior in the presence of cGMP substrate, was the increased cGMP hydrolytic activity in the presence of increasing concentrations of cGMP substrate. This was discovered by comparing 0.25 μ M, 2 μ M and 5 μ M concentrations of cGMP in the presence of PDE Peak B after a second DEAE separation to rule out cAMP hydrolysis and to rule out this new enzyme

being a previously identified PDE5. Higher cGMP concentrations evoked disproportionately greater cGMP hydrolysis with PDE Peak B, as shown in Figure 2.

These observations suggest that cGMP binding to the Peak B enzyme causes a conformational change in the enzyme. This confirms the advantage of using the native
5 enzyme from neoplastic cells, but this invention is not limited to the native form of the enzyme having the characteristics set forth above.

F. Zaprinst- and Sildenafil-Insensitivity of PDE Peak B Relative to Peak A, and Their Effects on Other PDE Inhibitors

Different PDE inhibitors were studied using twelve concentrations of drug from 0.01
10 to 100 μM and substrate concentration of 0.25 μM ^3H -cGMP. IC_{50} values were calculated with variable slope, sigmoidal curve fits using Prism 2.01 (GraphPad). The results are shown in Table 1. While compounds E4021 and zaprinast inhibited Peak A (with high affinities), IC_{50} values calculated against the novel PDE activity in Peak B (Section IIB) are significantly increased (>50 fold). This confirms that Peak A is a PDE5. These data further illustrate that
15 the novel PDE activity of this invention is, for all practical purposes, zaprinast-insensitive and E4021-insensitive.

Table 1
Comparison of PDE Inhibitors Against Peak A and Section IA
Peak B (cGMP Hydrolysis)

Compound	PDE Family Inhibitor	IC ₅₀ Peak A (μM)	IC ₅₀ Peak B (μM)	Ratio (IC ₅₀ PeakA/Peak B)
E4021	5	0.003	8.4	0.0004
Zaprinast	5	1.4	>30	<0.05
Compound E	5 and others	0.38	0.37	1.0
Sulindac sulfide	5 and others	50	50	1.0
Vinpocetine	1	>100	>100	
EHNA	2	>100	3.7	
Indolidan	3	31	>100	<0.31
Rolipram	4	>100	>100	
Sildenafil	5	.0003	>10	<.00003

5

By contrast, sulindac sulfide and Compound E competitively inhibited both Peaks A and B phosphodiesterases at the same potency (IC₅₀=0.38 μM for PDE Peak A; 0.37 μM for PDE Peak B).

There is significance for the treatment of neoplasia and the selection of useful compounds for such treatment in the fact that Peak B (either form of it) is zaprinast-insensitive whereas Peaks A and B are both sensitive to sulindac sulfide and Compound E. We have tested zaprinast, E4021 and sildenafil to ascertain whether they induce apoptosis or inhibit the growth of neoplastic cells, and have done the same for Compound E. As explained below, zaprinast by itself does not have significant apoptosis-inducing or growth-inhibiting properties, whereas sulindac sulfide and Compound E are precisely the opposite. In other words, the ability of a compound to inhibit both PDE Peaks A and B correlates with its ability to induce apoptosis in neoplastic cells, whereas if a compound (e.g., zaprinast) has specificity for PDE Peak A only, that compound will not by itself induce apoptosis.

G. Insensitivity of The Novel PDE Peak B To Incubation With cGMP-Dependent Protein Kinase G

Further differences between PDE Peak A and the novel Peak B (Section IIB) were observed in their respective cGMP-hydrolytic activities in the presence of varying concentrations of cGMP-dependent protein kinase G (which phosphorylates typical PDE5). Specifically, Peak A and Peak B fractions from Section IIB were incubated with different concentrations of protein kinase G at 30°C for 30 minutes. Cyclic GMP hydrolysis of both peaks has assayed after phosphorylation was attempted. Consistent with previously published information about PDE5, Peak A showed increasing cGMP hydrolysis activity in response to protein kinase G incubation, indicating that Peak A was phosphorylated. Peak B was unchanged, however (i.e., was not phosphorylated and insensitive to incubation with cGMP-dependent protein kinase G). These data are consistent with Peak A being an isoform consistent with the known PDE5 family and Peak B from Section IIB being a novel cGMP-specific PDE activity.

H. Novel Peak B In Prostate and Breast Cancer Cell Lines

The novel Peak B was also isolated from two other neoplastic cell lines, a breast cancer cell line, HTB-26, and a prostate cancer cell line, LnCAP, by a procedure similar to the one above used to isolate it from SW480. The protocol was modified in several respects. To provide even greater reproducibility to allow comparison of different cell lines, a Pharmacia AKTA FPLC was used to control sample loading and elution on an 18 mL DEAE TrisAcryl M column. SW840 was run by this same procedure multiple times to provide a reference of Peak B. 200-400 million cells of SW480 were used for the profiles. 70 million cells of LnCAP were used for a profile (see Figures 22 and 23), and in a separate experiment 32 million cells of HTB-26 were used for a profile (see Figures 20 and 21). After re-suspending cells in homogenization buffer, samples were manually homogenized. FPLC buffer A was 8 mM TRIS-acetate, 5 mM Mg acetate, 0.1 mM EDTA, pH 7.5 and buffer B was 8 mM TRIS-acetate, 5 mM Mg acetate, 0.1 mM EDTA, 1 M Na acetate, pH 7.5. Supernatants were loaded onto the column at 1 mL per minute, followed by a wash with 60 mL buffer A at 1 mL per minute. A gradient was run from 0-15% buffer B in 60 mL, 15-50% buffer B in 60 mL, and 50-100% buffer B in 16 mL. During the gradient 1.5 mL

fractions were collected. Peaks of cGMP PDE activity eluted around fraction 65 that was at 400 mM Na acetate (see Figures 20-23). This activity was measured at 0.25 μ M cGMP (indicating submicromolar affinity for cGMP). Rolipram, a PDE4-specific drug, inhibited most of the cAMP PDE activity (i.e. the cAMP activity was due to PDE4), indicating that the
5 Peak B's cGMP activity was specific for cGMP over cAMP. None of the three Peak B's (from SW480, HTB-26, and LnCAP) showed stimulation with calcium/calmodulin and all were resistant to 100 nM E4021, a specific PDE5-specific inhibitor like zaprinast (see Figures 20 and 22). The Peak B's also showed a dramatic increase in activity when substrate was increased from 0.25 μ M to 5 μ M cGMP (suggesting positively cooperative kinetics) (see
10 Figures 21 and 23). Also, the three peaks show similar inhibition by exisulind and Compound I, below.

III. PROTEIN KINASE G AND β -CATENIN INVOLVEMENT -- IN GENERAL

A series of experiments were performed to ascertain what effect, if any, an anti-
15 neoplastic cGMP-specific PDE inhibitor such as exisulind had on cGMP-dependent protein kinase G ("PKG") in neoplastic cells containing either the adenomatous polyposis coli gene ("APC gene") defect or a defect in the gene coding for β -catenin. As explained below, such an inhibitor causes an elevation in PKG activity in such neoplastic cells. That increase in activity was not only due to increased activation of PKG in cells containing either defect, but
20 also to increased expression of PKG in cells containing the APC defect. In addition, when PKG from neoplastic cells with either defect is immunoprecipitated, it precipitates with β -catenin.

β -catenin has been implicated in a variety of different cancers because researchers have found high levels of it in patients with neoplasias containing mutations in the APC
25 tumor-suppressing gene. People with mutations in this gene at birth often develop thousands of small tumors in the lining of their colon. When it functions properly, the APC gene codes for a normal APC protein that is believed to bind to and regulate β -catenin. Thus, the discovery that PKG in neoplastic cells containing either the APC gene defect or the β -catenin defect is bound to β -catenin indeed strongly implicates PKG in one of the major cellular
30 pathways that leads to cancer. In addition, the relationship between cGMP-specific inhibition

and PKG elevation upon treatment with SAANDs links cGMP to the PKG/ β -catenin/APC defect in such cells.

This latter link is further buttressed by the observation that β -catenin itself is reduced when neoplastic cells containing the APC defect or the β -catenin defect are exposed to a
5 SAAND. This reduction in β -catenin is initiated by PKG itself. PKG phosphorylates β -catenin -- which is another novel observation associated with this invention. The phosphorylation of β -catenin allows β -catenin to be degraded by ubiquitin-proteasomal system.

This phosphorylation of β -catenin by PKG is important in neoplastic cells because it
10 circumvents the effect of the APC and β -catenin mutations. The mutated APC protein affects the binding of the β -catenin bound to the mutant APC protein, which change in binding has heretofore been thought to prevent the phosphorylation of β -catenin by GSK-3 β kinase. In the case of mutant β -catenin, an elevation of PKG activity also allows the mutant β -catenin to be phosphorylated. Elevating PKG activity in neoplasia with cGMP-PDE inhibition allows
15 for β -catenin phosphorylation (leading to its degradation) in neoplastic cells containing either type of mutation.

In short, these findings not only lead to new pharmaceutical screening methods to identify further SAAND candidate compounds, but also buttress the role of cGMP-specific PDE inhibition in therapeutic approaches to neoplasia. This observation may also explain the
20 unexpectedly broad range of neoplasias SAANDs can inhibit since both neoplasia with and without the APC defect can be treated, as explained above.

IV. SCREENING PHARMACEUTICAL COMPOSITIONS USING THE PDES

A. In General

25 The novel PDE of this invention and PDE2 are useful with or without PDE5 to identify compounds that can be used to treat or prevent neoplasias, and that are not characterized by serious side effects.

Cancer and precancer may be thought of as diseases that involve unregulated cell growth. Cell growth involves a number of different factors. One factor is how rapidly cells

proliferate, and another involves how rapidly cells die. Cells can die either by necrosis or apoptosis depending on the type of environmental stimuli. Cell differentiation is yet another factor that influences tumor growth kinetics. Resolving which of the many aspects of cell growth is affected by a compound is important to the discovery of a relevant target for pharmaceutical therapy. Screening assays based on this technology can be combined with other tests to select compounds that have growth inhibiting and pro-apoptotic activity.

This invention is the product of several important discoveries. First, the present inventors discovered that desirable inhibitors of tumor cell growth induce premature death of cancer cells by apoptosis (see, Piazza, G.A., et al., *Cancer Research*, 55(14), 3110-16, 1995). Second, several of the present inventors unexpectedly discovered compounds that selectively induce apoptosis without substantial COX inhibition also inhibit PDE5. In particular, and contrary to leading scientific studies, desirable compounds for treating neoplastic lesions inhibit PDE5 (EC 3.1.4.17). PDE5 is one of at least ten gene families of phosphodiesterase. PDE5 and the novel PDE of this invention are unique in that they selectively degrade cyclic GMP and not cAMP, while the other families of PDE selectively degrade/hydrolyze cAMP and not cGMP or non-selectively degrade both cGMP and cAMP. Preferably, desirable compounds used to treat neoplasia do not substantially inhibit non-selective or cAMP degrading phosphodiesterase types.

B. COX Screening

A preferred embodiment of the present invention involves determining the cyclooxygenase inhibition activity of a given compound, and determining the cGMP specific PDE inhibitory activity of the compound. The test compounds are assessed for their ability to treat neoplastic lesions either directly or indirectly by comparing their activities against known compounds useful for treating neoplastic lesions. A standard compound that is known to be effective for treating neoplastic lesions without causing gastric irritation is 5-fluoro-2-methyl-1-(p-methylsulfonylbenzylidene)-3-indenylacetic acid ("exisulind"). Other useful compounds for comparative purposes include those that are known to inhibit COX, such as indomethacin and the sulfide metabolite of sulindac: 5-fluoro-2-methyl-1-(p-methylsulfinylbenzylidene)-3-indenylacetic acid ("sulindac sulfide"). Other useful

compounds for comparative purposes include those that are known to inhibit cGMP-specific PDEs, such as 1-(3-chloroanilino)-4-phenylphthalazine ("MY5445").

As used herein, the term "precancerous lesion" includes syndromes represented by abnormal neoplastic, including dysplastic, changes of tissue. Examples include dysplastic
5 growths in colonic, breast, prostate or lung tissues, or conditions such as dysplastic nevus syndrome, a precursor to malignant melanoma of the skin. Examples also include, in addition to dysplastic nevus syndromes, polyposis syndromes, colonic polyps, precancerous lesions of the cervix (i.e., cervical dysplasia), esophagus, lung, prostatic dysplasia, prostatic intraneoplasia, breast and/or skin and related conditions (e.g., actinic keratosis), whether the
10 lesions are clinically identifiable or not.

As used herein, the terms "carcinoma" or "cancer" refers to lesions which are cancerous. Examples include malignant melanomas, breast cancer, prostate cancer and colon cancer. As used herein, the terms "neoplasia" and "neoplasms" refer to both cancerous and pre-cancerous lesions.

As used herein, the abbreviation PG represents prostaglandin; PS represents prostaglandin synthetase; PGE₂ represents prostaglandin E₂; PDE represents phosphodiesterase; COX represents cyclooxygenase; cyclic nucleotide, RIA represents -
15 radioimmunoassay.

COX inhibition by a compound can be determined by either of two methods. One
20 method involves measuring PGE₂ secretion by intact HL-60 cells following exposure to the compound being screened. The other method involves measuring the activity of purified cyclooxygenases (COXs) in the presence of the compound. Both methods involve protocols previously described in the literature, but preferred protocols are set forth below.

Compounds can be evaluated to determine whether they inhibit the production of
25 prostaglandin E₂ ("PGE₂"), by measuring PGE₂. Using an enzyme immunoassay (EIA) kit for PGE₂, such as commercially available from Amersham, Arlington Heights, IL U.S.A. Suitable cells include those that make an abundance of PG, such as HL-60 cells. HL-60 cells are human promyelocytes that are differentiated with DMSO into mature granulocytes (see, Collins, S.J., Ruscetti, F.W., Gallagher, R.E. and Gallo, R.C., "Normal Functional
30 Characteristics of Cultured Human Promyelocytic Leukemia Cells (HL-60) After Induction of Differentiation By Dimethylsulfoxide", *J. Exp. Med.*, 149:969-974, 1979). These

differentiated cells produce PGE₂ after stimulation with a calcium ionophore, A23187 (see, Kargman, S., Prasit, P. and Evans, J.F., "Translocation of HL-60 Cell 5-Lipoxygenase", *J. Biol. Chem.*, 266: 23745-23752, 1991). HL-60 cells are available from the ATCC (ATCC:CCL240). They can be grown in a RPMI 1640 medium supplemented with 20%
5 heat-inactivated fetal bovine serum, 50 U/mL penicillin and 50 µg/mL streptomycin in an atmosphere of 5% CO₂ at 37°C. To induce myeloid differentiation, cells are exposed to 1.3% DMSO for 9 days and then washed and resuspended in Dulbecco's phosphate-buffered saline at a concentration of 3x10⁶ cells/mL.

The differentiated HL-60 cells (3x10⁶ cells/mL) are incubated for 15 minutes at 37°C
10 in the presence of the compounds tested at the desired concentration. Cells are then stimulated by A23187 (5x10⁻⁶ M) for 15 minutes. PGE₂ secreted into the external medium is measured as described above.

As indicated above, a second method to assess COX inhibition of a compound is to measure the COX activity in the presence of a test compound. Two different forms of
15 cyclooxygenase (COX-I and COX-2) have been reported in the literature to regulate prostaglandin synthesis. COX-2 represents the inducible form of COX while COX-I represents a constitutive form. COX-I activity can be measured using the method described by Mitchell et al. ("Selectivity of Nonsteroidal Anti-inflammatory Drugs as Inhibitors of Constitutive and Inducible Cyclooxygenase," *Proc. Natl. Acad. Sci. USA.*, 90:11693-11697,
20 1993, which is incorporated herein by reference) using COX-I purified from ram seminal vesicles as described by Boopathy & Balasubramanian, "Purification And Characterization Of Sheep Platelet Cyclooxygenase" (*Biochem. J.*, 239:371-377, 1988, which is incorporated herein by reference). COX-2 activity can be measured using COX-2 purified from sheep placenta as described by Mitchell et al., 1993, *supra*.

25 The cyclooxygenase inhibitory activity of a drug can be determined by methods known in the art. For example, Boopathy & Balasubramanian, 1988, *supra*, described a procedure in which prostaglandin H synthase 1 (Cayman Chemical, Ann Arbor, Michigan) is incubated at 37°C for 20 minutes with 100 µM arachidonic acid (Sigma Chemical Co.), cofactors (such as 1.0 mM glutathione, 1.0 mM hydroquinone, 0.625 µM hemoglobin and
30 1.25 mM CaCl₂ in 100 mM Tris-HCl, pH 7.4) and the drug to be tested. Following incubation, the reaction can be terminated with trichloroacetic acid. After stopping the

reaction by adding thiobarbituric acid and malonaldehyde, enzymatic activity can then be measured spectrophotometrically at 530 nm.

Obviously, a compound that exhibits a lower COX-I or COX-2 inhibitory activity in relation to its greater combined PDE5/novel PDE/PDE2 inhibitory activities may be a desirable compound.

The amount of COX inhibition is determined by comparing the activity of the cyclooxygenase in the presence and absence of the test compound. Residual (i.e., less than about 25%) or no COX inhibitory activity at a concentration of about 100 μ M is indicative that the compound should be evaluated further for usefulness for treating neoplasia.

10 C. Determining Phosphodiesterase Inhibition Activity

Compounds can be screened for inhibitory effect on the activity of the novel phosphodiesterase of this invention using either the enzyme isolated as described above, a recombinant version, or using the novel PDE and/or PDE2 together with PDE5. Alternatively, cyclic nucleotide levels in whole cells are measured by RIA and compared to untreated and zaprinast-treated cells.

Phosphodiesterase activity can be determined using methods known in the art, such as a method using radioactive ^3H cyclic GMP (cGMP)(cyclic 3',5'-guanosine monophosphate) as the substrate for the PDE enzyme. (Thompson, W.J., Teraski, W.L., Epstein, P.M., Strada, S.J., *Advances in Cyclic Nucleotide Research*, 10:69-92, 1979, which is incorporated herein by reference). In brief, a solution of defined substrate ^3H -cGMP specific activity (0.2 μ M; 100,000 cpm; containing 40 mM Tris-HCl (pH 8.0), 5 mM MgCl_2 and 1 mg/mL BSA) is mixed with the drug to be tested in a total volume of 400 μ L. The mixture is incubated at 30°C for 10 minutes with isolated PDE of this invention. Reactions are terminated, for example, by boiling the reaction mixture for 75 seconds. After cooling on ice, 100 μ L of 0.5 mg/mL snake venom (*O. Hannah* venom available from Sigma) is added and incubated for 10 minutes at 30°C. This reaction is then terminated by the addition of an alcohol, e.g. 1 mL of 100% methanol. Assay samples are applied to 1 mL Dowex 1-X8 column; and washed with 1 mL of 100% methanol. The amount of radioactivity in the breakthrough and the wash from the column is combined and measured with a scintillation counter. The degree of phosphodiesterase inhibition is determined by calculating the amount of radioactivity in drug-

treated reactions and comparing against a control sample (a reaction mixture lacking the tested compound but with drug solvent).

Alternatively, the ability of desirable compounds to inhibit the phosphodiesterases of this invention is reflected by an increase in cGMP in neoplastic cells exposed to a compound being screened. The amount of PDE activity can be determined by assaying for the amount of cyclic GMP in the extract of treated cells using radioimmunoassay (RIA). In this procedure, HT-29 or SW-480 cells are plated and grown to confluency. As indicated above, SW-480 contains both PDE5 and the novel PDE of this invention, so when PDE activity is evaluated in this fashion, a combined cGMP hydrolytic activity is assayed simultaneously.

The test compound is then incubated with the cell culture at a concentration of compound between about 200 μ M to about 200 pM. About 24 to 48 hours thereafter, the culture media is removed from the cells, and the cells are solubilized. The reaction is stopped by using 0.2N HCl/50% MeOH. A sample is removed for protein assay. Cyclic GMP is purified from the acid/alcohol extracts of cells using anion-exchange chromatography, such as a Dowex column. The cGMP is dried, acetylated according to published procedures, such as using acetic anhydride in triethylamine, (Steiner, A.L., Parker, C.W., Kipnis, D.M., *J. Biol. Chem.*, 247(4):1106-13, 1971, which is incorporated herein by reference). The acetylated cGMP is quantitated using radioimmunoassay procedures (Harper, J., Brooker, G., *Advances in Nucleotide Research*, 10:1-33, 1979, which is incorporated herein by reference). Iodinated ligands (tyrosine methyl ester) of derivatized cyclic GMP are incubated with standards or unknowns in the presence of antisera and appropriate buffers. Antiserum may be produced using cyclic nucleotide-haptene directed techniques. The antiserum is from sheep injected with succinyl-cGMP-albumin conjugates and diluted 1/20,000. Dose-interpolation and error analysis from standard curves are applied as described previously (Seibert, A.F., Thompson, W.J., Taylor, A., Wilbourn, W.H., Barnard, J. and Haynes, J., *J. Applied Physiol.*, 72:389-395, 1992, which is incorporated herein by reference).

In addition, the culture media may be acidified, frozen (-70°C) and also analyzed for cGMP and cAMP.

In addition to observing increases in the content of cGMP in neoplastic cells caused by desirable compounds, decreases in content of cAMP have also been observed. It has been observed that a particularly desirable compound (i.e., one that selectively induces apoptosis

in neoplastic cells, but not substantially in normal cells) follows a time course consistent with cGMP-specific PDE inhibition as one initial action resulting in an increased cGMP content within minutes. Secondly, treatment of neoplastic cells with a desirable anti-neoplastic compound leads to decreased cAMP content within 24 hours. The intracellular targets of
5 drug actions are being studied further, but current data support the concept that the initial rise in cGMP content and the subsequent fall in cAMP content precede apoptosis in neoplastic cells exposed to desirable compounds.

The change in the ratio of the two cyclic nucleotides may be a more accurate tool for evaluating desirable cGMP-specific phosphodiesterase inhibition activity of test compounds,
10 rather than measuring only the absolute value of cGMP, only cGMP-specific phosphodiesterase inhibition, or only the level of cGMP hydrolysis. In neoplastic cells not treated with anti-neoplastic compounds, the ratio of cGMP content/cAMP content is in the 0.03-0.05 range (i.e., 300-500 fmol/mg protein cGMP content over 6000-8000 fmol/mg protein cAMP content). After exposure to desirable anti-neoplastic compounds, that ratio
15 increases several fold (preferably at least about a three-fold increase) as the result of an initial increase in cyclic GMP and the later decrease in cyclic AMP.

Specifically, it has been observed that particularly desirable compounds achieve an initial increase in cGMP content in treated neoplastic cells to a level of cGMP greater than about 500 fmol/mg protein. In addition, particularly desirable compounds cause the later
20 decrease in cAMP content in treated neoplastic cells to a level of cAMP less than about 4000 fmol/mg protein.

To determine the content of cyclic AMP, radioimmunoassay techniques similar to those described above for cGMP are used. Basically, cyclic nucleotides are purified from acid/alcohol extracts of cells using anion-exchange chromatography, dried, acetylated
25 according to published procedures and quantitated using radioimmunoassay procedures. Iodinated ligands of derivatized cyclic AMP and cyclic GMP are incubated with standards or unknowns in the presence of specific antisera and appropriate buffers.

Verification of the cyclic nucleotide content may be obtained by determining the turnover or accumulation of cyclic nucleotides in intact cells. To measure intact cell cAMP,
30 ³H-adenine pre-labeling is used according to published procedures (Whalin, M.E., Garrett Jr., R.L., Thompson, W.J., and Strada, S.J. "Correlation of cell-free brain cyclic nucleotide

phosphodiesterase activities to cyclic AMP decay in intact brain slices", *Sec. Mess. and Phos. Protein Research*, 12:311-325, 1989, which is incorporated herein by reference). The procedure measures flux of labeled ATP to cyclic AMP and can be used to estimate intact cell adenylate cyclase or cyclic nucleotide phosphodiesterase activities depending upon the specific protocol. Cyclic GMP accumulation was too low to be studied with intact cell pre-labeling according to published procedures (Reynolds, P.E., S.J. Strada and W.J. Thompson, "Cyclic GMP Accumulation In Pulmonary Microvascular Endothelial Cells Measured By Intact Cell Prelabeling," *Life Sci.*, 60:909-918, 1997, which is incorporated herein by reference).

10 The PDE inhibitory activity effect of a compound can also be determined from a tissue sample. Tissue biopsies from humans or tissues from anesthetized animals are collected from subjects exposed to the test compound. Briefly, a sample of tissue is homogenized in 500 μ l of 6% TCA. A known amount of the homogenate is removed for protein analysis. The remaining homogenate is allowed to sit on ice for 20 minutes to allow
15 for the protein to precipitate. Next, the homogenate is centrifuged for 30 minutes at 15,000g at 4°C. The supernatant is recovered, and the pellet recovered. The supernatant is washed four times with five volumes of water saturated diethyl ether. The upper ether layer is discarded between each wash. The aqueous ether extract is dried in a speed vac. Once dried, the sample can be frozen for future use, or used immediately. The dried extract is dissolved
20 in 500 μ l of assay buffer. The amount of cGMP-specific inhibition is determined by assaying for the amount of cyclic nucleotides using RIA procedures as described above.

 The amount of inhibition is determined by comparing the activity of the novel PDE (or PDE2) in the presence and absence of the compound. Inhibition of the novel PDE activity (or PDE2) is indicative that the compound is useful for treating neoplasia.
25 Significant inhibitory activity greater than that of the benchmark, exisulind, preferably greater than 50% at a concentration of 10 μ M or below, is indicative that a compound should be further evaluated for antineoplastic properties. Preferably, the IC₅₀ value for the novel PDE inhibition should be less than 50 μ M for the compound to be further considered for potential use.

D. Determining Whether A Compound Reduces Tumor Cell Growth

In an alternate embodiment, the method of the present invention involves further determining whether the compound reduces the growth of tumor cells. Various cell lines can be used in the sample depending on the tissue to be tested. For example, these cell lines
5 include: SW-480 – colonic adenocarcinoma; HT-29 – colonic adenocarcinoma, A-427 – lung adenocarcinoma carcinoma; MCF-7 – breast adenocarcinoma; and UACC-375 – melanoma line; and DU145 – prostate carcinoma. Cytotoxicity data obtained using these cell lines are indicative of an inhibitory effect on neoplastic lesions. These cell lines are well characterized, and are used by the United States National Cancer Institute in their screening
10 program for new anti-cancer drugs.

A compound's ability to inhibit tumor cell growth can be measured using the HT-29 human colon carcinoma cell line obtained from ATCC. HT-29 cells have previously been characterized as a relevant colon tumor cell culture model (Fogh, J., and Trempe, G. *In: Human Tumor Cells in Vitro*, J. Fogh (eds.), Plenum Press, New York, pp. 115-159, 1975).
15 HT-29 cells are maintained in RPMI media supplemented with 5% fetal bovine calf serum (Gemini Bioproducts, Inc., Carlsbad, CA) and 2 mM glutamine, and 1% antibiotic-antimycotic in a humidified atmosphere of 95% air and 5% CO₂ at 37°C. Briefly, HT-29 cells are plated at a density of 500 cells/well in 96 well microtiter plates and incubated for 24 hours at 37°C prior to the addition of compound. Each determination of cell number
20 involved six replicates. After six days in culture, the cells are fixed by the addition of cold trichloroacetic acid to a final concentration of 10% and protein levels are measured using the sulforhodamine B (SRB) colorimetric protein stain assay as previously described by Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J.T., Bokesch, H., Kenney, S., and Boyd, M.R., "New Colorimetric Assay For Anticancer-Drug Screening,"
25 *J. Natl. Cancer Inst.* 82: 1107-1112, 1990, which is incorporated herein by reference.

In addition to the SRB assay, a number of other methods are available to measure growth inhibition and could be substituted for the SRB assay. These methods include counting viable cells following trypan blue staining, labeling cells capable of DNA synthesis with BrdU or radiolabeled thymidine, neutral red staining of viable cells, or MTT staining of
30 viable cells.

Significant tumor cell growth inhibition greater than about 50% at a dose of 100 μ M or below is further indicative that the compound is useful for treating neoplastic lesions. Preferably, an IC₅₀ value is determined and used for comparative purposes. This value is the concentration of drug needed to inhibit tumor cell growth by 50% relative to the control.

- 5 Preferably, the IC₅₀ value should be less than 100 μ M for the compound to be considered further for potential use for treating neoplastic lesions.

E. Determining Whether A Compound Induces Apoptosis

In a second alternate embodiment, the screening method of the present invention further involves determining whether the compound induces apoptosis in cultures of tumor
10 cells.

Two distinct forms of cell death may be described by morphological and biochemical criteria: necrosis and apoptosis. Necrosis is accompanied by increased permeability of the plasma membrane; the cells swell and the plasma membrane ruptures within minutes. Apoptosis is characterized by membrane blebbing, condensation of cytoplasm and the
15 activation of endogenous endonucleases.

Apoptosis occurs naturally during normal tissue turnover and during embryonic development of organs and limbs. Apoptosis also is induced by cytotoxic T-lymphocytes and natural killer cells, by ionizing radiation and by certain chemotherapeutic drugs. Inappropriate regulation of apoptosis is thought to play an important role in many
20 pathological conditions including cancer, AIDS, or Alzheimer's disease, etc. Compounds can be screened for induction of apoptosis using cultures of tumor cells maintained under conditions as described above. Treatment of cells with test compounds involves either pre- or post-confluent cultures and treatment for two to seven days at various concentrations. Apoptotic cells are measured in both the attached and "floating" compartments of the
25 cultures. Both compartments are collected by removing the supernatant, trypsinizing the attached cells, and combining both preparations following a centrifugation wash step (10 minutes, 2000 rpm). The protocol for treating tumor cell cultures with sulindac and related compounds to obtain a significant amount of apoptosis has been described in the literature. (See, Piazza, G.A., et al., *Cancer Research*, 55:3110-16, 1995, which is incorporated herein
30 by reference). The novel features include collecting both floating and attached cells,

identification of the optimal treatment times and dose range for observing apoptosis, and identification of optimal cell culture conditions.

Following treatment with a compound, cultures can be assayed for apoptosis and necrosis by florescent microscopy following labeling with acridine orange and ethidium bromide. The method for measuring apoptotic cell number has previously been described by Duke & Cohen, "Morphological And Biochemical Assays Of Apoptosis," *Current Protocols In Immunology*, Coligan et al., eds., 3.17.1-3.17.16 (1992), which is incorporated herein by reference.

For example, floating and attached cells can be collected by trypsinization and washed three times in PBS. Aliquots of cells can be centrifuged. The pellet can then be re-suspended in media and a dye mixture containing acridine orange and ethidium bromide prepared in PBS and mixed gently. The mixture can then be placed on a microscope slide and examined for morphological features of apoptosis.

Apoptosis can also be quantified by measuring an increase in DNA fragmentation in cells that have been treated with test compounds. Commercial photometric EIA for the quantitative, *in vitro* determination of cytoplasmic histone-associated-DNA-fragments (mono- and oligonucleosomes) are available (Cell Death Detection ELISA^{okys}, Cat. No. 1,774,425, Boehringer Mannheim). The Boehringer Mannheim assay is based on a sandwich-enzyme-immunoassay principle using mouse monoclonal antibodies directed against DNA and histones, respectively. This allows the specific determination of mono- and oligonucleosomes in the cytoplasmatic fraction of cell lysates.

According to the vendor, apoptosis is measured in the following fashion. The sample (cell-lysate) is placed into a streptavidin-coated microtiter plate ("MTP"). Subsequently, a mixture of anti-histone-biotin and anti-DNA peroxidase conjugate are added and incubated for two hours. During the incubation period, the anti-histone antibody binds to the histone-component of the nucleosomes and simultaneously fixes the immunocomplex to the streptavidin-coated MTP via its biotinylation. Additionally, the anti-DNA peroxidase antibody reacts with the DNA component of the nucleosomes. After removal of unbound antibodies by a washing step, the amount of nucleosomes is quantified by the peroxidase retained in the immunocomplex. Peroxidase is determined photometrically with ABTS7 (2,2'-Azido-[3-ethylbenzthiazolin-sulfonate]) as substrate.

For example, SW-480 colon adenocarcinoma cells are plated in a 96-well MTP at a density of 10,000 cells per well. Cells are then treated with test compound, and allowed to incubate for 48 hours at 37°C. After the incubation, the MTP is centrifuged, and the supernatant is removed. The cell pellet in each well is then resuspended in lysis buffer for 30 minutes. The lysates are then centrifuged and aliquots of the supernatant (i.e., the cytoplasmic fraction) are transferred into a streptavidin-coated MTP. Care is taken not to shake the lysed pellets (i.e. cell nuclei containing high molecular weight, unfragmented DNA) in the MTP. Samples are then analyzed.

Fold stimulation ($FS = OD_{max}/OD_{veh}$), an indicator of apoptotic response, is determined for each compound tested at a given concentration. EC_{50} values may also be determined by evaluating a series of concentrations of the test compound.

Statistically significant increases in apoptosis (i.e., greater than 2 fold stimulation at a concentration of 100 μ M) are further indicative that the compound is useful for treating neoplastic lesions. Preferably, the EC_{50} value for apoptotic activity should be less than 100 μ M for the compound to be further considered for potential use for treating neoplastic lesions. EC_{50} is herein defined as the concentration that causes 50% induction of apoptosis relative to vehicle treatment.

F. Mammary Gland Organ Culture Model Tests

Test compounds identified by the above methods can be tested for antineoplastic activity by their ability to inhibit the incidence of pre-neoplastic lesions in a mammary gland organ culture system. This mouse mammary gland organ culture technique has been successfully used by other investigators to study the effects of known antineoplastic agents such as certain NSAIDs, retinoids, tamoxifen, selenium, and certain natural products, and is useful for validation of the screening method of the present invention.

For example, female BALB/c mice can be treated with a combination of estradiol and progesterone daily, in order to prime the glands to be responsive to hormones *in vitro*. The animals are sacrificed, and thoracic mammary glands are excised aseptically and incubated for ten days in growth media supplemented with insulin, prolactin, hydrocortisone, and aldosterone. DMBA (7,12-dimethylbenz(a)anthracene) is added to medium to induce the formation of premalignant lesions. Fully developed glands are then deprived of prolactin,

hydrocortisone, and aldosterone, resulting in the regression of the glands but not the pre-malignant lesions. .

5 The test compound is dissolved in DMSO and added to the culture media for the duration of the culture period. At the end of the culture period, the glands are fixed in 10% formalin, stained with alum carmine, and mounted on glass slides. The incidence of forming mammary lesions is the ratio of the glands with mammary lesions to glands without lesions. The incidence of mammary lesions in test compound treated glands is compared with that of the untreated glands.

10 The extent of the area occupied by the mammary lesions can be quantitated by projecting an image of the gland onto a digitation pad. The area covered by the gland is traced on the pad and considered as 100% of the area. The space covered by each of the non-regressed structures is also outlined on the digitization pad and quantitated by the computer.

EXPERIMENTAL RESULTS

A number of compounds were examined in the various protocols and screened for potential use in treating neoplasia. The results of these tests are reported below. The test compounds are hereinafter designated by a letter code that corresponds to the following:

- A - rac-threo-(E)-1-(N,N'-diethylaminoethanethio)-1-(butan-1',4'-olido)-[3',4':1,2]-6-fluoro-2-methyl-3-(p-methylsulfonylbenzylidene)-indan;
- 10 B - (Z)-5-Fluoro-2-methyl-1-(3,4,5-trimethoxybenzylidene)-3-acetic acid;
- C - (Z)-5-Fluoro-2-methyl-1-(p-chlorobenzylidene)-3-acetic acid;
- D - rac-(E)-1-(butan-1',4'-olido)-[3',4':1,2]-6-fluoro-2-methyl-3-(p-methylsulfonylbenzylidene)-1S-indanyl-N-acetylcysteine;
- 15 E - (Z)-5-Fluoro-2-methyl-1-(3,4,5-trimethoxybenzylidene)-3-indenylacetamide, N-benzyl;
- 20 F - (Z)-5-Fluoro-2-methyl-1-(p-methylsulfonylbenzylidene)-3-indenylacetamide, N,N'-dicyclohexyl;
- G - ribo-(E)-1-Triazolo-[2',3':1'',3'']-1-(butan-1',4'-olido)-[3',4':1,2]-6-fluoro-2-methyl-3-(p-methylsulfonylbenzylidene)-indan; and
- 25 H - rac-(E)-1-(butan-1',4'-olido)-[3',4':1,2]-6-fluoro-2-methyl-3-(p-methylsulfonylbenzylidene)-1S-indanyl-glutathione).

Example 1 - COX Inhibition Assay

30 Reference compounds and test compounds were analyzed for their COX inhibitory activity in accordance with the protocol for the COX assay, *supra*. Figure 4 shows the effect

of various concentrations of either sulindac sulfide or exisulind on purified cyclooxygenase (Type 1) activity. Cyclooxygenase activity was determined using purified cyclooxygenase from ram seminal vesicles as described previously (Mitchell et al, *supra*). The IC₅₀ value for sulindac sulfide was calculated to be approximately 1.76 μ M, while that for exisulind was greater than 10,000 μ M. These data show that sulindac sulfide, but not exisulind, is a COX-I inhibitor. Similar data were obtained for the COX-2 isoenzyme (Thompson, et al., Journal of the National Cancer Institute, 87: 1259-1260, 1995).

Figure 5 shows the effect of test compounds B and E on COX inhibition. COX activity was determined as for the compounds shown in Figure 4. The data show that neither test compound B and E significantly inhibit COX-I.

Table 2
Cyclooxygenase inhibitory activity for a series of compounds

Reference compounds	% Inhibition at 100 μ M
Indomethacin	95
MY5445	94
Sulindac sulfide	97
Exisulind	<25
Test compounds	% Inhibition at 100 μ M
A	<25
B	<25
C	87
D	<25
E	<25

In accordance with the protocol, *supra*, compounds A through E were evaluated for COX inhibitory activity as reported in Table 2 above. Compound C was found to inhibit COX greater than 25% at a 100 μ M dose, and therefore, would not be selected for further screening.

Example 2 - cGMP PDE inhibition assay

Reference compounds and test compounds were analyzed for their cGMP PDE inhibitory activity in accordance with the protocol for the assay described *supra*. Figure 6

shows the effect of various concentrations of sulindac sulfide and exisulind on either PDE4 or cGMP PDE activity purified from human colon HT-29 cultured tumor cells, as described previously (W. J. Thompson et al., *supra*). The IC_{50} value of sulindac sulfide for inhibition of PDE4 was 41 μ M, and for inhibition of cGMP PDE was 17 μ M. The IC_{50} value of
5 exisulind for inhibition of PDE4 was 181 μ M, and for inhibition of cGMP PDE was 56 μ M. These data show that both sulindac sulfide and exisulind inhibit phosphodiesterase activity. Both compounds show selectivity for the cGMP PDE isoenzyme forms over PDE4 isoforms.

Figure 7 shows the effects of sulindac sulfide on either cGMP or cAMP production as determined in cultured HT-29 cells in accordance with the assay described, *supra*. HT-29
10 cells were treated with sulindac sulfide for 30 minutes and cGMP or cAMP was measured by conventional radioimmunoassay method. As indicated, sulindac sulfide increased the levels of cGMP by greater than 50% with an EC_{50} value of 7.3 μ M (Figure 7A). Levels of cAMP were unaffected by treatment, although a known PDE4 inhibitor, rolipram, increased cAMP (Figure 7B). The data demonstrate the pharmacological significance of inhibiting cGMP
15 PDE, relative to PDE4.

Figure 8 shows the effect of the indicated dose of test compound B on either cGMP PDE or PDE4 isozymes of phosphodiesterase. The calculated IC_{50} value was 18 μ M for cGMP PDE and was 58 μ M for PDE4.

Figure 9 shows the effect of the indicated dose of test compound E on either PDE4 or
20 cGMP PDE. The calculated IC_{50} value was 0.08 μ M for cGMP PDE and greater than 25 μ M for PDE4.

Table 3
cGMP PDE inhibitory activity among a series of compounds

Reference compounds		% Inhibition at 10 μ M
	Indomethacin	34
5	MY5445	86
	Sulindac sulfide	97
	Exisulind	39
Test compounds		% Inhibition at 10 μ M
	A	<25
10	B	<25
	C	<25
	D	36
	E	75

15 The above compounds in Table 3 were evaluated for PDE inhibitory activity, as described in the protocol *supra*. Of the compounds that did not inhibit COX, only compound E was found to cause greater than 50% inhibition at 10 μ M. As noted in Figure 8, compound B showed inhibition of greater than 50% at a dose of 20 μ M. Therefore, depending on the dosage level used in a single dose test, some compounds may be screened out that otherwise
20 may be active at slightly higher dosages. The dosage used is subjective and may be lowered after active compounds are found at certain levels to identify even more potent compounds.

Example 3 - Apoptosis assay

Reference compounds and test compounds were analyzed for their novel PDE
25 inhibitory activity in accordance with the protocols for the assay, *supra*. In accordance with those protocols, Figure 10 shows the effects of sulindac sulfide and exisulind on apoptotic and necrotic cell death. HT-29 cells were treated for six days with the indicated dose of either sulindac sulfide or exisulind. Apoptotic and necrotic cell death was determined previously (Duke and Cohen, In: Current Protocols in Immunology, 3.17.1 - 3.17.16, New
30 York, John Wiley and Sons, 1992). The data show that both sulindac sulfide and exisulind are capable of causing apoptotic cell death without inducing necrosis. All data were collected from the same experiment.

Figure 11 shows the effect of sulindac sulfide and exisulind on tumor growth inhibition and apoptosis induction as determined by DNA fragmentation. Top Figure (11A); growth inhibition (open symbols, left axis) and DNA fragmentation (closed symbols, right axis) by exisulind. Bottom Figure (11B); growth inhibition (open symbols) and DNA fragmentation (closed symbols) by sulindac sulfide. Growth inhibition was determined by the SRB assay after six days of treatment. DNA fragmentation was determined after 48 hours of treatment. All data were collected from the same experiment.

Figure 12 shows the apoptosis inducing properties of compound E. HT-29 colon adenocarcinoma cells were treated with the indicated concentration of compound E for 48 hours and apoptosis was determined by the DNA fragmentation assay. The calculated EC_{50} value was 0.05 μ M.

Figure 13 shows the apoptosis inducing properties of compound B. HT-29 colon adenocarcinoma cells were treated with the indicated concentration of compound B for 48 hours and apoptosis was determined by the DNA fragmentation assay. The calculated EC_{50} value was approximately 175 μ M.

Table 4
Apoptosis-inducing activity among a series of compounds

Reference compounds		Fold induction at 100 μ M
20	Indomethacin	<2.0
	MY5445	4.7
	Sulindac sulfide	7.9
	Exisulind	<2.0
	E4021	<2.0
25	Zaprinast	<2.0
	Sildenafil	<2.0
	EHNA	<2.0
Test compounds		Fold induction at 100 μ M
	A	<2.0
30	B	3.4
	C	5.6
	D	<2.0
	E	4.6

In accordance with the fold induction protocol, *supra*, the compounds A through E were tested for apoptosis inducing activity, as reported in Table 4 above. Compounds B, C and E showed significant apoptotic inducing activity, greater than 2.0 fold, at a dosage of 100 μ M. Of these three compounds, at this dosage only B and E did not inhibit COX but did
 5 inhibit cGMP-specific PDE.

The apoptosis inducing activity for a series of phosphodiesterase inhibitors was determined. The data are presented in Table 5 below. HT-29 cell were treated for 6 days with various inhibitors of phosphodiesterase. Apoptosis and necrosis were determined morphologically after acridine orange and ethidium bromide labeling in accordance with the
 10 assay described, *supra*. The data show that the novel cGMP-specific PDE is useful for screening compounds that induce apoptosis of HT-29 cells.

Table 5
Apoptosis-Induction Data for PDE Inhibitors

15	Inhibitor	Reported Selectivity	% Apoptosis	% Necrosis
	Vehicle		8	6
	8-methoxy-IBMX	PDE1	2	1
	Milrinone	PDE3	18	0
	RO-20-1724	PDE4	11	2
20	MY5445	PDE5	80	5
	IBMX	Non-selective	4	13

Example 4 - Growth inhibition assay

Reference compounds and test compounds were analyzed for their PDE5 inhibitory
 25 activity in accordance with the protocol for the assay *supra*. Figure 14 shows the inhibitory effect of various concentrations of sulindac sulfide and exisulind on the growth of HT-29 cells. HT-29 cells were treated for six days with various doses of exisulind (triangles) or sulindac sulfide (squares) as indicated. Cell number was measured by a sulforhodamine assay as previously described (Piazza et al., *Cancer Research*, 55: 3110-3116, 1995). The
 30 IC₅₀ value for sulindac sulfide was approximately 45 μ M and 200 μ M for exisulind. The data show that both sulindac sulfide and exisulind are capable of inhibiting tumor cell growth.

Figure 15 shows the growth inhibitory and apoptosis-inducing activity of sulindac sulfide. A time course experiment is shown involving HT-29 cells treated with either vehicle, 0.1% DMSO (open symbols) or sulindac sulfide, 120 μ M (closed symbols). Growth inhibition (15A top) was measured by counting viable cells after trypan blue staining. Apoptosis (15B bottom) was measured by morphological determination following staining with acridine orange and ethidium bromide as described previously (Duke and Cohen, in: Current Protocols in Immunology, 3.17.1 - 3.17.16, New York, John Wiley and Sons, 1992). The data demonstrate that sulindac sulfide is capable of inhibiting tumor cell growth, and that the effect is accompanied by an increase in apoptosis. All data were collected from the same experiment.

Figure 16 shows the growth inhibitory activity of test compound E. HT-29 colon adenocarcinoma cells were treated with the indicated concentration of compound E for six days and cell number was determined by the SRB assay. The calculated IC₅₀ value was 0.04 μ M.

Table 6
Growth-inhibitory activity among a series of compounds

Reference compounds	% Inhibition at 100 μ M
Indomethacin	75
MY5445	88
Sulindac sulfide	88
Exisulind	<50
E4021	<50
sildenafil	<50
zaprinas	<50
Test compounds	% Inhibition at 100 μ M
A	68
B	77
C	80
D	78
E	62

In accordance with the screening protocol of section *supra*, compounds A through E were tested for growth inhibitory activity, as reported in Table 6 above. All the test compounds showed activity exceeding a 100 μ M single dose test.

The growth inhibitory activity for a series of phosphodiesterase inhibitors was determined. The data are shown in Table 7 below. HT-29 cells were treated for 6 days with various inhibitors of phosphodiesterase. Cell growth was determined by the SRB assay described, *supra*. The data below taken with those above show that inhibitors of the novel

5 PDE were effective for inhibiting tumor cell growth.

Table 7
Growth Inhibitory Data for PDE Inhibitors

10	Inhibitor	Reported Selectivity	Growth inhibition (IC ₅₀ , μ M)
	8-methoxy-IBMX	PDE1	>200 μ M
	Milrinone	PDE3	>200 μ M
	RO-20-1724	PDE4	>200 μ M
	MY5445	PDE5	5 μ M
15	IBMX	Non-selective	>100 μ M
	Zaprinast	PDE5	>100 μ M
	Sildenafil	PDE5	>100 μ M
	E4021	PDE5	>100 μ M

20 To show the effectiveness of this screening method on various forms of neoplasia, compounds were tested on numerous cell lines. The effects of sulindac sulfide and exisulind on various cell lines were determined. The data are shown in Table 8 below. The IC₅₀ values were determined by the SRB assay. The data show the broad effectiveness of these compounds on a broad range of neoplasias, with effectiveness at comparable dose range.

25 Therefore, compounds identified and selected by this invention should be useful for treating multiple forms of neoplasia.

Table 8
Growth Inhibitory Data of Various Cell Lines

Cell Type/ Tissue specificity	IC ₅₀ (μM)		
	Sulindac sulfide	Exisulind	Compound E*
HT-29, Colon	60	120	0.10
HCT116, Colon	45	90	
MCF7/S, Breast	30	90	
UACC375, Melanoma	50	100	
A-427, Lung	90	130	
Bronchial Epithelial Cells	30	90	
NRK, Kidney (non ras-transformed)	50	180	
KNRK, Kidney (ras transformed)	60	240	
Human Prostate Carcinoma PC3		82	0.90
Colo 205			1.62
DU-145			0.10
HCT-15			0.60
MDA-MB-231			0.08
MDA-MB-435			0.04

*Determined by neutral red assay as described by Schmid et al., in Proc. AACR Vol 39, p. 195 (1998).

Example 5 - Activity in mammary gland organ culture model

Figure 17 shows the inhibition of premalignant lesions in mammary gland organ culture by sulindac metabolites. Mammary gland organ culture experiment were performed as previously described (Mehta and Moon, *Cancer Research*, 46: 5832-5835, 1986). The results demonstrate that sulindac and exisulind effectively inhibit the formation of premalignant lesions, while sulindac sulfide was inactive. The data support the hypothesis that cyclooxygenase inhibition is not necessary for the anti-neoplastic properties of desired compounds.

ANALYSIS

To select compounds for treating neoplasia, this invention provides a rationale for comparing experimental data of test compounds from several protocols. Within the framework of this invention, test compounds can be ranked according to their potential use

for treating neoplasia in humans. Those compounds having desirable effects may be selected for additional testing and subsequent human use.

Qualitative data of various test compounds and the several protocols are shown in Table 9 below. The data show that exisulind, compound B and compound E exhibit the
5 appropriate activity to pass the screen of four assays: lack of COX inhibition, and presence of effective cGMP-specific PDE inhibition, growth inhibition and apoptosis induction. The activity of these compounds in the mammary gland organ culture validates the effectiveness of this invention. The qualitative valuations of the screening protocols rank compound E best, then compound B and then exisulind.

Table 9
Activity Profile of Various Compounds

Compound	COX	PDE	Growth	Mammary	
	Inhibition	Inhibition	Inhibition	Apoptosis	Gland Organ Culture
Exisulind	-	++	++	++	+++
Sulindac sulfide	++++	+++	+++	+++	-
MY5445	++++	+++	+++	+++	+
A	-	-	+++	++	++
B	-	+++	+++	+++	++
D	-	-	++	-	-
E	-	++++	++++	++++	++++
F	-	-	++	+	-
G	-	-	+++	++	+++
H	-	-	++	-	-

Table 9 Code: Activity of compounds based on evaluating a series of experiments involving tests for maximal activity and potency.

- Not active

+ Slightly active

++ Moderately active

+++ Strongly active

++++ Highly active

Also disclosed is a novel assay for PKG activity, which is used in the screening methods of this invention, but also has more general usefulness in assaying for PKG activity for other purposes (e.g., for studying the role of PKG in normal cellular function). For explanation purposes, it is useful to describe the PKG assay first, before describing how PKG activity can be useful in drug evaluation in ascertaining whether a compound is potentially useful in the treatment of neoplasia.

The Novel PKG Assay

The novel PKG assay of this invention involves binding to solid phase plural amino acid sequences, each of which contain at least the cGMP-binding (cGB) domain and the phosphorylation site of phosphodiesterase type 5 ("PDE5"). That sequence is known and described in the literature below. Preferably, the bound PDE5 sequence does not include the catalytic domain of PDE5 as described below. One way to bind the PDE5 sequences to a solid phase is to express those sequences as a fusion protein of the PDE5 sequence and one member of an amino acid binding pair, and chemically link the other member of that amino acid binding pair to a solid phase (e.g., beads). One binding pair that can be used is glutathione S-transferase ("GST") and glutathione ("GSH"), with the GST being expressed as a fusion protein with the PDE5 sequence described above, and the GSH bound covalently to the solid phase. In this fashion, the PDE5 sequence/GST fusion protein can be bound to a solid phase simply by passing a solution containing the fusion protein over the solid phase, as described below.

RT-PCR method is used to obtain the cGB domain of PDE5 with forward and reverse primers designed from bovine PDE5A cDNA sequence (*McAllister-Lucas L. M. et al, J. Biol. Chem. 268, 22863-22873, 1993*) and the selection among PDE 1-10 families. 5'-3', Inc. kits for total RNA followed by oligo (dT) column purification of mRNA are used with HT-29 cells. Forward primer (GAA-TTC-TGT-TAG-AAA-AGC-CAC-CAG-AGA-AAT-G, 203-227) and reverse primer (CTC-GAG-CTC-TCT-TGT-TTC-TTC-CTC-TGC-TG, 1664-1686) are used to synthesize the 1484 bp fragment coding for the phosphorylation site and both low and high affinity cGMP binding sites of human PDE5A (203-1686 bp, cGB-PDE5). The synthesized cGB-PDE5 nucleotide fragment codes for 494 amino acids with 97% similarity to bovine PDE5A. It is then cloned into pGEX-5X-3 glutathione-S-transferase (GST) fusion vector (Pharmacia Biotech) with tac promoter, and EcoRI and XhoI cut sites. The fusion vector is then transfected into E. Coli BL21 (DE3) bacteria (Invitrogen). The transfected BL21 bacteria are grown to log phase and then IPTG is added as an inducer. The induction is carried out at 20°C for 24 hrs. The bacteria are harvested and lysed. The soluble cell lysate is incubated with GSH conjugated Sepharose 4B (GSH-Sepharose 4B). The GST-cGB-PDE5 fusion protein can bind to the GSH-Sepharose beads, and the other proteins are washed off from the beads with excessive cold PBS.

The expressed GST-cGB-PDE5 fusion protein is displayed on 7.5% SDS-PAGE gel as a 85 Kd protein. It is characterized by its cGMP binding and phosphorylation by protein kinases G and A. It displays two cGMP binding sites and the K_d is $1.6 \pm 0.2 \mu\text{M}$, which is close to $K_d = 1.3 \mu\text{M}$ of the native bovine PDE5. The GST-cGB-PDE5 on GSH conjugated
5 sepharose beads can be phosphorylated in vitro by cGMP-dependent protein kinase and cAMP-dependent protein kinase A. The K_m of GST-cGB-PDE5 phosphorylation by PKG is $2.7 \mu\text{M}$ and the V_{max} is $2.8 \mu\text{M}$, while the K_m of BPDEtide phosphorylation is $68 \mu\text{M}$. The phosphorylation by PKG shows molecular phosphate incorporated into GST-cGB-PDE5 protein on a one-to-one ratio.

10 To assay a liquid sample believed to contain PKG using the PDE5-bound solid phase described above, the sample and the solid phase are mixed with phosphorylation buffer containing ^{32}P - γ -ATP. The solution is incubated for 30 minutes at 30°C to allow for phosphorylation of the PDE5 sequence by PKG to occur, if PKG is present. The solid phase is then separated from solution (e.g., by centrifugation or filtration) and washed with
15 phosphate-buffered saline ("PBS") to remove any remaining solution and to remove any unreacted ^{32}P - γ -ATP.

The solid phase can then be tested directly (e.g., by liquid scintillation counter) to ascertain whether ^{32}P is incorporated. If ^{32}P is incorporated, that indicates that the sample contained PKG since PKG phosphorylates PDE5. If the PDE5 is bound via fusion protein, as
20 described above, the PDE5-containing fusion protein can be eluted from the solid phase with SDS buffer, and the eluent can be assayed for ^{32}P incorporation. This is particularly advantageous if there is the possibility that other proteins are present, since the eluent can be processed (e.g., by gel separation) to separate various proteins from each other so that the fusion protein fraction can be assayed for ^{32}P incorporation. The phosphorylated fusion
25 protein can be eluted from the solid phase with SDS buffer and further resolved by electrophoresis. If gel separation is performed, the proteins can be stained to see the position(s) of the protein, and ^{32}P phosphorylation of the PDE5 portion of the fusion protein by PKG can be measured by exposure of the gel to X-ray film. If ^{32}P is made visible on X-ray film, that indicates that the original sample contained PKG, which phosphorylated the
30 PDE5 portion of the fusion protein eluted from the solid phase.

Preferably in the assay, one should add to the assay buffer an excess (e.g., 100 fold) of protein kinase inhibitor ("PKI") which specifically and potently inhibits protein kinase A ("PKA") without inhibiting PKG. Inhibiting PKA is desirable since it may contribute to the phosphorylation of the PKG substrate (e.g., PDE5). By adding PKI, any contribution to phosphorylation by PKA will be eliminated, and any phosphorylation detected is highly likely to be due to PKG alone.

A kit can be made for the assay of this invention, which kit contains the following pre-packaged reagents in separate containers:

1. Cell lysis buffer: 50 mM Tris-HCl, 1% NP-40, 150 mM NaCl, 1 mM EDTA, 1mM Na₃VO₄, 1 mM NaF, 500μM IBMX, proteinase inhibitors.
2. Protein kinase G solid phase substrate: recombinant GST-cGB-PDE5 bound Sepharose 4B (50% slurry).
3. 2x Phosphorylation buffer: ³²P-γ-ATP (3000 mCi/mmol, 5~10 μCi/assay), 10 mM KH₂PO₄, 10 mM K₂HPO₄, 200 μM ATP, 5 mM MgCl₂.
4. PKA Protein Kinase I Inhibitor

Disposable containers and the like in which to perform the above reactions can also be provided in the kit.

From the above, one skilled in the analytical arts will readily envision various ways to adapt the assay formats described to still other formats. In short, using at least a portion of PDE5 (or any other protein that can be selectively phosphorylated by PKG), the presence and relative amount (as compared to a control) of PKG can be ascertained by evaluating phosphorylation of the phosphorylatable protein, using a labeled phosphorylation agent.

SAANDs Increase PKG Activity In Neoplastic Cells

Using the PKG assay described above, the following experiments were performed to establish that SAANDs increase PKG activity due either to increase in PKG expression or an increase in cGMP levels (or both) in neoplastic cells treated with a SAAND.

Test Procedures

Two different types of PDE inhibitors were evaluated for their effects on PKG in neoplastic cells. A SAAND, exisulind, was evaluated since it is anti-neoplastic. Also, a non-SAAND classic PDE5 inhibitor, E4021, was evaluated to ascertain whether PKG elevation

was simply due to classic PDE5 inhibition, or whether PKG elevation was involved in the pro-apoptotic effect of SAANDs inhibition of PDE5 and the novel PDE disclosed in United States Patent Application No. 09/173,375 to Liu et al filed October 15, 1998.

To test the effect of cGMP-specific PDE inhibition on neoplasia containing the APC mutation, SW480 colon cancer cells were employed. SW 480 is known to contain the APC mutation. About 5 million SW480 cells in RPMI 5% serum are added to each of 8 dishes:

2 - 10cm dishes --- 30 μ L DMSO vehicle control (without drug),

3 - 10cm dishes ---200 μ M, 400 μ M, 600 μ M exisulind, and

3 - 10cm dishes --- E4021; 0.1 μ M, 1 μ M and 10 μ M.

10 The dishes are incubated for 48 hrs at 37°C in 5% CO₂ incubator.

The liquid media are aspirated from the dishes (the cells will attach themselves to the dishes). The attached cells are washed in each dish with cold PBS, and 200 μ L cell lysis buffer (i.e., 50 mM Tris-HCl, 1% NP-40, 150 mM NaCl, 1 mM EDTA, 1mM Na₃VO₄, 1 mM NaF, 500 μ M IBMX with proteinase inhibitors) is added to each dish. Immediately after the cell lysis buffer is added, the lysed cells are collected by scraping the cells off each dish. The cell lysate from each dish is transferred to a microfuge tube, and the microfuge tubes are incubated at 4°C for 15 minutes while gently agitating the microfuge tubes to allow the cells to lyse completely. After lysis is complete, the microfuge tubes are centrifuged full speed (14,000 r.p.m.) for 15 minutes. The supernatant from each microfuge tube is transferred to a fresh microfuge tube.

A protein assay is then performed on the contents of each microfuge tube because the amount of total protein will be greater in the control than in the drug-treated samples, if the drug inhibits cell growth. Obviously, if the drug does not work, the total protein in the drug-treated samples should be virtually the same as control. In the above situation, the control and the E-4021 microfuge tubes needed dilution to normalize them to the high-dose exisulind-treated samples (the lower dose groups of exisulind had to be normalized to the highest dose exisulind sample). Thus, after the protein assays are performed, the total protein concentration of the various samples must be normalized (e.g., by dilution).

For each drug concentration and control, two PKG assays are performed, one with added cGMP, and one without added cGMP, as described in detail below. The reason for

performing these two different PKG assays is that cGMP specifically activates PKG. When PKG activity is assayed using the novel PKG assay of this invention, one cannot ascertain whether any increase the PKG activity is due to increased cGMP in the cells (that may be caused by cGMP-specific PDE inhibition) or whether the PKG activity level is due to an increased expression of PKG protein. By determining PKG activity in the same sample both with and without added cGMP, one can ascertain whether the PKG activity increase, if any, is due to increased PKG expression. Thus, if an anti-neoplastic drug elevates PKG activity relative to control, one can establish if the drug-induced increase is due to increased PKG protein expression (as opposed to activation) in the drug-treated sample if (1) the drug-treated sample with extra cGMP exhibits greater PKG activity compared to the control sample with extra cGMP, and (2) the drug-treated sample without extra cGMP exhibits greater PKG activity relative to control.

After parallel samples with and without added cGMP are prepared, 50 μ L of each cell lysate is added to 20 μ L of the PDE5/GST solid phase substrate slurry described above. For each control or drug cell lysate sample to be evaluated, the reaction is started by adding phosphorylation buffer containing 10 μ Ci 32 P- γ -ATP solution (200 μ M ATP, 4.5 mM MgCl₂; 5 mM KH₂PO₄; 5 mM K₂HPO₄;) to each mixture. The resultant mixtures are incubated at 30°C for 30 minutes. The mixtures are then centrifuged to separate the solid phase, and the supernatant is discarded. The solid phase in each tube is washed with 700 μ L cold PBS. To the solid phase, Laemmli sample buffer (Bio-Rad) (30 μ L) is added. The mixtures are boiled for 5 minutes, and loaded onto 7.5% SDS-PAGE. The gel is run at 150 V for one hour. The bands obtained are stained with commassie blue to visualize the 85 Kd GST-PDE5 fusion protein bands, if present. The gel is dried, and the gel is laid on x-ray film which, if the PDE5 is phosphorylated, the film will show a corresponding darkened band. The darkness of each band relates to the degree of phosphorylation.

As shown in Figures 18A and 18B, the SAAND exisulind causes PKG activity to increase in a dose-dependent manner in both the samples with added cGMP and without added cGMP relative to the control samples with and without extra cGMP. This is evidenced by the darker appearances of the 85 Kd bands in each of the drug-treated samples. In addition, the SW480 samples treated with exisulind show a greater PKG phosphorylation activity with added cGMP in the assay relative to the samples treated with vehicle with added

cGMP. Thus, the increase in PKG activity in the drug-treated samples is not due only to the activation of PKG by the increase in cellular cGMP when the SAAND inhibits cGMP-specific PDE, the increase in PKG activity in neoplasia harboring the APC mutation is due to increased PKG expression as well.

5 Also the fact that the E4021-treated SW480 samples do not exhibit PKG activation relative to control (see Figures 18A and 18B) shows that the increased PKG activation caused by SAANDs in neoplasia containing the APC mutation is not simply due to inhibition of classic PDE5.

10 As an analytic technique for evaluating PKG activation, instead of x-ray film exposure as described above, the 85 Kd band from the SDS page can be evaluated for the degree of phosphorylation by cutting the band from the gel, and any ³²P incorporated in the removed band can be counted by scintillation (beta) counter in the ³²P window.

15 To test the effect of cGMP-specific PDE inhibition on neoplasia containing the β -catenin mutation, HCT116 colon cancer cells were employed. HCT116 is known to contain the β -catenin mutation, but is known not to contain the APC mutation.

20 The same procedure is used to grow the HCT116 cells as is used in the SW480 procedure described above. In this experiment, only exisulind and controls were used. The exisulind-treated cells yielded PKG that was phosphorylated to a greater extent than the corresponding controls, indicating that PKG activation occurred in the drug-treated cells that is independent of the APC mutation.

 Thus, for the purposes of the present invention, " β -catenin" refers to wild type and/or mutant forms of that protein.

Confirmation of Increased PKG Expression and Decreased β -Catenin In SW 480 By

Western Blot

25 As demonstrated above, SAANDs cause an increase in PKG expression and an increase in cGMP level, both of which cause an increase in PKG activity in SAANDs-treated neoplastic cells. This increase in PKG protein expression was further verified by relatively quantitative western blot, as described below.

30 SW480 cells treated with exisulind as described previously are harvested from the microfuge tubes by rinsing once with ice-cold PBS. The cells are lysed by modified RIPA

buffer for 15 minutes with agitation. The cell lysate is spun down in a cold room. The supernatants are transferred to fresh microcentrifuge tubes immediately after spinning. BioRad DC Protein Assay (Temecula, CA) is performed to determine the protein concentrations in samples. The samples are normalized for protein concentration, as described above.

50 µg of each sample is loaded onto a 10% SDS gel. SDS-PAGE is performed, and the proteins then are transferred to a nitrocellulose membrane. The blotted nitrocellulose membrane is blocked in freshly prepared TBST containing 5% nonfat dry milk for one hour at room temperature with constant agitation.

A goat-anti-PKG primary antibody is diluted to the recommended concentration/dilution in fresh TBST/5% nonfat dry milk. The nitrocellulose membrane is placed in the primary antibody solution and incubated one hour at room temperature with agitation. The nitrocellulose membrane is washed three times for ten minutes each with TBST. The nitrocellulose membrane is incubated in a solution containing a secondary peroxidase (POD) conjugated rabbit anti-goat antibody for 1 hour at room temperature with agitation. The nitrocellulose membrane is washed three times for ten minutes each time with TBST. The detection is performed by using Boehringer Mannheim BM blue POD substrate.

As graphically illustrated in Figure 19, exisulind causes the drop of β -catenin and the increase of PKG, which data were obtained by Western blot. SW480 cells were treated with exisulind or vehicle (0.1% DMSO) for 48 hours. 50 µg supernatant of each cell lysate was loaded onto a 10% SDS-gel and blotted to a nitrocellulose membrane, and the membrane was probed with rabbit-anti- β -catenin and rabbit anti-PKG antibodies.

SAANDs Reduce β -Catenin Levels in Neoplastic Cells

This observation was made by culturing SW480 cells with either 200, 400 or 600 µM exisulind or vehicle (0.1% DMSO). The cells are harvested 48 hours post treatment and processed for immunoblotting. Immuno-reactive protein can be detected by Western blot. Western blot analysis demonstrated that expression of β -catenin was reduced by 50 % in the exisulind-treated cells as compared to control. These results indicate that β -catenin is reduced by SAANDs treatment. Together with the results above, establishing PKG activity

increases with such treatment, and the results below, establishing that β -catenin is phosphorylated by PKG, these results indicate that the reduction of β -catenin in neoplastic cells is initiated by activation of PKG. Thus, using PKG activity in neoplasia as a screening tool to select compounds as anti-neoplastics is useful.

5

The Phosphorylation of β -catenin By PKG

In vitro, PKG phosphorylates β -catenin. The experiment that established this involves immunoprecipitating the β -catenin-containing complex from SW480 cells (not treated with any drug) in the manner described below under " β -catenin immunoprecipitation." The immunoprecipitated complex, while still trapped on the solid phase (i.e., beads) is mixed with ^{32}P - γ -ATP and pure PKG (100 units). Corresponding controls without added PKG are prepared.

The protein is released from the solid phase by SDS buffer, and the protein-containing mixture is run on a 7.5% SDS-PAGE gel. The running of the mixture on the gel removes excess ^{32}P - γ -ATP from the mixture. Any ^{32}P - γ -ATP detected in the 93Kd β -catenin band, therefore, is due to the phosphorylation of the β -catenin. Any increase in ^{32}P - γ -ATP detected in the 93 Kd β -catenin band treated with extra PKG relative to the control without extra PKG, is due to the phosphorylation of the β -catenin in the treated band by the extra PKG.

The results we obtained were that there was a noticeable increase in phosphorylation in the band treated with PKG as compared to the control, which exhibited minimal, virtually undetectable phosphorylation. This result indicates that β -catenin can be phosphorylated by PKG.

The Phosphorylation of Mutant β -catenin By PKG

The same procedure described in the immediately preceding section was performed with HCT116 cells, which contain no APC mutation, but contain a β -catenin mutation. The results of those experiments also indicate that mutant β -catenin is phosphorylated by PKG.

Thus, for the purposes of the present invention, the phosphorylation of β -catenin refers to the phosphorylation of wild type and/or mutant forms of that protein.

30

β -Catenin Precipitates With PKG

Supernatants of both SW480 and HCT116 cell lysates are prepared in the same way described above in the Western Blot experiments. The cell lysates are pre-cleared by adding 150 μ l of protein A Sepharose bead slurry (50%) per 500 μ g of cell lysate and incubating at 4°C for 10 minutes on a tube shaker. The protein A beads are removed by centrifugation at 14,000 x g at 4°C for 10 minutes. The supernatants are transferred to a fresh centrifuge tubes. 10 μ g of the rabbit polyclonal anti- β -catenin antibody (Upstate Biotechnology, Lake Placid, New York) are added to 500 μ g of cell lysate. The cell lysate/antibody mixture is gently mixed for 2 hours at 4°C on a tube shaker. The immunocomplex is captured by adding 150 μ l protein A Sepharose bead slurry (75 μ l packed beads) and by gently rocking the mixture on a tube shaker for overnight at 4°C. The Sepharose beads are collected by pulse centrifugation (5 seconds in the microcentrifuge at 14,000 rpm). The supernatant fraction is discarded, and the beads are washed 3 times with 800 μ l ice-cold PBS buffer. The Sepharose beads are resuspended in 150 μ l 2 x sample buffer and mixed gently. The Sepharose beads are boiled for 5 minutes to dissociate the immunocomplexes from the beads. The beads are collected by centrifugation and SDS-PAGE is performed on the supernatant.

A Western blot is run on the supernatant, and the membrane is then probed with a rabbit-anti- β -catenin antibody. Then the membrane is washed 3 times for 10 minutes each time with TBST to remove excess anti- β -catenin antibody. A goat, anti-rabbit antibody conjugated to horseradish peroxidase is added, followed by a one hour incubation at room temperature. When that is done, one can visualize the presence of β -catenin with an HRPO substrate. In this experiment, we could clearly visualize the presence of β -catenin.

To detect PKG on the same membrane, the anti- β -catenin antibody conjugate is first stripped from the membrane with a 62 mM tris-HCl buffer (pH 7.6) with 2 % SDS and 100 μ M 2 β -mercaptoethanol in 55°C water bath for 0.5 hour. The stripped membrane is then blocked in TBST with 5% non-fat dried milk for one hour at room temperature while agitating the membrane. The blocked, stripped membrane is then probed with rabbit polyclonal anti-PKG antibody (Calbiochem, LaJolla, CA), that is detected with goat, anti-rabbit second antibody conjugated to HRPO. The presence of PKG on the blot membrane is visualized with an HRPO substrate. In this experiment, the PKG was, in fact, visualized.

Given that the only proteins on the membrane are those that immunoprecipitated with β -catenin in the cell supernatants, this result clearly establishes that PKG was physically linked to the protein complex containing the β -catenin in the cell supernatants.

The same Western blot membrane was also probed after stripping with anti-GSK3- β antibody to ascertain whether it also co-precipitated with β -catenin. In that experiment, we also detected GSK3- β on the membrane, indicating that the GSK3- β precipitated with the GSK3- β and PKG, suggesting that the three proteins may be part of the same complex. Since GSK3- β and β -catenin form part of the APC complex in normal cells, this indicates that PKG may be part of the same complex, and may be involved in the phosphorylation of β -catenin as part of that complex.

Anti-Neoplastic Pharmaceutical Compositions Containing cGMP PDE Inhibitors

One drug that was also invented before its mechanism of action was found to involve cGMP inhibition and before it was known to meet the selection criterion of this invention is (Z)-5-fluoro-2-methyl-(4-pyridylidene)-3-(N-benzyl)indenylacetamide hydrochloride ("Compound I"). It has been demonstrated in *in vitro* and *in vivo* evaluations as anti-neoplastic having activities against a broad range of neoplasias. It is also safe in animal studies and in a single, escalating dose human study.

As one skilled in the art will recognize from the data presented below, Compound I can safely be given to animals at doses far beyond the tolerable (and in many cases toxic) doses of conventional chemotherapeutics or anti-neoplastic NSAIDs. For example, in an acute toxicity study in rats, single oral doses of Compound I administered (in a 0.5% carboxy-methylcellulose vehicle) at doses up to and including 2000 mg/kg resulted in no observable signs of toxicity. At 4000 mg/kg, body weight gains were slightly reduced. A single dose of 1000 mg/kg administered intraperitoneally resulted in reduced body weight gain, with mesenteric adhesions seen in some animals from this group at necropsy.

In dogs, the administration of Compound I in capsules at 1000 mg/kg resulted in no signs of toxicity to the single group of two male and two female dogs. Due to the nature of Compound I capsules, this dose necessitated the use of at least 13 capsules to each animal, which was judged to be the maximum number without subjecting the animals to stress.

Therefore, these dogs were subsequently administered seven consecutive doses of 1000 mg/kg/day. At no time in either dosing phase were any obvious signs of drug-related effects observed.

Thus, on a single-dose basis, Compound I is not acutely toxic. Based on the findings of these studies, the oral LD₅₀ of Compound I was considered to be greater than 1000 mg/kg in dogs and 4000 mg/kg in rats, and the intraperitoneal LD₅₀ was considered to be greater than 1000 mg/kg in rats.

A seven-day dose-range finding study in rats, where Compound I was evaluated by administering it at doses of 0, 50, 500 or 2000 mg/kg/day resulted in no observable signs of toxicity at 50 mg/kg/day. At 500 mg/kg/day, treatment-related effects were limited to an increase in absolute and relative liver weights in female rats. At 2000 mg/kg/day, effects included labored breathing and/or abnormal respiratory sounds, decreased weights gains and food consumption in male rats, and increased liver weights in female rats. No hematological or blood chemistry changes nor any microscopic pathology changes, were seen at any dose level.

A 28-day study in rats was also carried out at 0, 50, 500 and 2000 mg/kg/day. There were no abnormal clinical observations attributed to Compound I, and body weight changes, ophthalmoscopic examinations, hematological and blood chemistry values and urinalysis examinations were unremarkable. No macroscopic tissue changes were seen at necropsy. Organ weight data revealed statistically significant increase in liver weights at 2000 mg/kg/day, and statistically significant increases in thyroid weights for the 2000 mg/kg/day group. The slight increases at the lower doses were not statistically significant. Histopathological evaluation of tissues indicated the presence of traces of follicular cell hypertrophy, increased numbers of mitotic figures (suggestive of possible cell proliferation) in the thyroid gland and mild centrilobular hypertrophy in the liver. These changes were generally limited to a small number of animals at the 2000 mg/kg/day dose, although one female at 500 mg/kg/day had increased mitotic figures in the thyroid gland. The findings in the liver may be indicative of a very mild stimulation of microsomal enzymes, resulting in increased metabolism of thyroid hormones, which in turn resulted in thyroid stimulation. Thus, one skilled in the art will recognize that these effects are extremely minimal compared to what one would expect at similar doses of conventional chemotherapeutics or NSAIDs.

To further establish the safety profile of Compound I, a study was performed to evaluate whether Compound I-induced apoptosis of prostate tumor cell lines was comparable to its effects on prostate epithelial cells derived from normal tissue. The androgen-sensitive prostate tumor cell line, LNCaP (from ATCC (Rockville, MD)) was propagated under standard conditions using RPMI 160 medium containing 5% fetal calve serum and 2 mM glutamine. Primary prostate epithelial cell cultures (PrEC) derived from normal prostate (from Clonetics Inc. (San Diego, CA)) were grown under the same conditions as the tumor cell line except a serum-free medium optimized for the growth of such cultures was used (Clonetics Inc). For the experiments, LNCaP or PrEC cells were seeded in 96 well plates at a density of 10,000 cells per well. After 24 hours, the cells were treated with either vehicle (0.1% DMSO) or 50 μ M Compound I (free base) solubilized in DMSO. After various drug treatment times (4, 24, 48, 72, or 99 hours) the cells were lysed and processed for measurement of histone-associated DNA as an indicator of apoptotic cell death (see, Piazza et al., *Cancer Research* 57: 2452-2459, 1997).

Figure 27 shows a time-dependent increase in the amount of histone-associated fragmented DNA in LNCaP cell cultures following treatment with 50 μ M Compound I (free base). A significant increase in fragmented DNA was detected after 24 hours of treatment, and the induction was sustained for up to 4 days of continuous treatment. By contrast, treatment of PrEC ("normal" prostate) cells with Compound I (50 μ M) did not affect DNA fragmentation for up to 4 days of treatment. These results demonstrate a selective induction of apoptosis in neoplastic cells, as opposed to normal cells. This is in marked contrast to conventional chemotherapeutics that induce apoptosis or necrosis in rapidly growing normal and neoplastic cells alike.

Identification of Additional Inhibitors

As to identifying structurally additional cGMP-specific PDE inhibiting compounds that can be effective therapeutically as anti-neoplastics, one skilled in the art has a number of useful model compounds disclosed herein (as well as their analogs incorporated by reference) that can be used as the bases for computer modeling of additional compounds having the same conformations but different chemically. For example, software such as that sold by Molecular Simulations Inc. release of WebLab® ViewerPro™ includes molecular

visualization and chemical communication capabilities. Such software includes functionality, including 3D visualization of known active compounds to validate sketched or imported chemical structures for accuracy. In addition, the software allows structures to be superimposed based on user-defined features, and the user can measure distances, angles, or
5 dihedrals.

 In this situation, since the structures of other active compounds are disclosed above, one can apply cluster analysis and 2D and 3D similarity search techniques with such software to identify potential new additional compounds that can then be screened and selected according to the selection criteria of this invention. These software methods rely upon the
10 principle that compounds, which look alike or have similar properties, are more likely to have similar activity, which can be confirmed using the selection criterion of this invention.

 Likewise, when such additional compounds are computer modeled, many such compounds and variants thereof can be synthesized using known combinatorial chemistry techniques that are commonly used by those of ordinary skill in the pharmaceutical industry.
15 Examples of a few for-hire combinatorial chemistry services include those offered by New Chemical Entities, Inc. of Bothell Washington, Protogene Laboratories, inc., of Palo Alto, California, Axys, Inc. of South San Francisco, California, Nanosyn, Inc. of Tucson, Arizona, Trega, Inc. of San Diego, California, and RBI, Inc. of Natick, Mass. There are a number of other for-hire companies. A number of large pharmaceutical companies have similar, if not
20 superior, in-house capabilities. In short, one skilled in the art can readily produce many compounds for screening from which to select promising compounds for treatment of neoplasia having the attributes of compounds disclosed herein.

 In addition, there are a number of commercially-known libraries of compounds usually made with combinatorial techniques. Such compounds can first be assessed using the
25 types of software explained above to ascertain whether they are conformationally similar to active compounds of the types disclosed herein. After identifying such conformationally similar compounds, the compounds can readily be screened according to the methods of this invention to yield anti-neoplastic cGMP PDE inhibitors.

 To further assist in identifying compounds that can be screened and then selected
30 using the criterion of this invention, knowing the binding of selected anti-neoplastic compounds to PDE5 protein is of interest. By the procedures discussed below, it was found

that preferable, desirable compounds meeting the selection criteria of this invention bind to the cGMP catalytic region of PDE5.

To establish this, a PDE5 sequence that does not include the catalytic domain was used. One way to produce such a sequence is to express that sequence as a fusion protein, preferably with glutathione S-transferase ("GST"). Production of a GST-cGB-PDE5 fusion
5 protein was carried out by the procedure described above in the section entitled The Novel PKG Assay.

A cGMP binding assay for compounds of interest (Francis S. H. et al, J. Biol. Chem. 255, 620-626, 1980) is done in a total volume of 100 μ L containing 5 mM sodium phosphate
10 buffer (pH=6.8), 1 mM EDTA, 0.25 mg/mL BSA, H^3 -cGMP (2 μ M, NEN) and the GST-cGB-PDE5 fusion protein (30 μ g /assay). Each compound to be tested is added at the same time as 3H -cGMP substrate, and the mixture is incubated at 22°C for 1 hour. Then, the mixture is transferred to Brandel MB-24 cell harvester with GF/B as the filter membrane followed by 2 washes with 10 mL of cold 5 mM potassium buffer (pH 6.8). The membranes are then cut
15 out and transferred to scintillation vials followed by the addition of 1 mL of H_2O and 6 mL of Ready SafeTM liquid scintillation cocktail to each vial. The vials are counted on a Beckman LS 6500 scintillation counter.

For calculation, blank samples are prepared by boiling the binding protein for 5 minutes, and the binding counts are < 1% when compared to unboiled protein. The
20 quenching by filter membrane or other debris are also calibrated.

PDE5 inhibitors, sulfide, exisulind, Compound B, Compound E, E4021 and zaprinast, and cyclic nucleotide analogs, cAMP, cyclic IMP, 8-bromo-cGMP, cyclic UMP, cyclic CMP, 8-bromo-cAMP, 2'-O-butyl-cGMP and 2'-O-butyl-cAMP are selected to test whether they could competitively bind to the cGMP binding sites of the GST-cGB-PDE5 protein. The
25 results were shown in Figure 24. cGMP specifically binds GST-cGB-PDE5 protein. Cyclic AMP, cUMP, cCMP, 8-bromo-cAMP, 2'-O-butyl-cAMP and 2'-O-butyl-cGMP did not compete with cGMP in binding. Cyclic IMP and 8-bromo-cGMP at high concentration (100 μ M) can partially compete with cGMP (2 μ M) binding. None of the PDE5 inhibitors showed any competition with cGMP in binding of GST-cGB-PDE5. Therefore, they do not bind to
30 the cGMP binding sites of PDE5.

However, Compound E does competitively (with cGMP) bind to PDE 5 (i.e., Peak A). (Compound E also competitively (with cGMP) binds to PDE Peak B.). Given that Compound E does not bind to the cGMP-binding site of PDE5, the fact that there is competitive binding between Compound E and cGMP at all means that desirable compounds
5 such as Compound E bind to the cGMP catalytic site on PDE5, information that is readily obtainable by one skilled in the art (with conventional competitive binding experiments) but which can assist one skilled in the art more readily to model other compounds. Thus, with the chemical structures of desirable compounds presented herein and the cGMP binding site information, one skilled in the art can model, identify and select (using the selection criteria
10 of this invention) other chemical compounds for use as therapeutics.

COMBINATION TREATMENT WITH A TOPOISOMERASE I INHIBITOR AND A PDE INHIBITOR

The method of this invention involves treating a patient with neoplasia with both an
15 topoisomerase I inhibitor and a cGMP-specific PDE inhibitor. There are a number of topoisomerase I inhibitors in addition to those mentioned above. For example, various topoisomerase I inhibitors are disclosed in U.S. Patent Nos. 5,767,142, 5,604,233, 5,677,286, and 5,106,742 which are incorporated herein by reference. Such compositions and others specifically referred to herein collectively disclose non-limiting examples of "topoisomerase I
20 inhibitors" as that term is used herein.

This invention involves using combination therapy to treat a patient with neoplasia. By treating a patient with this combination of pharmaceuticals, a topoisomerase I inhibitor and a cGMP-specific PDE inhibitor, therapeutic results can be achieved that are not seen with either drug alone. As explained above, exisulind is one example of an appropriate cGMP-
25 specific PDE inhibitor to be used in combination with a topoisomerase I inhibitor in the practice of this invention. Exisulind inhibits both PDE5 and the new cGMP-PDE, and treatment of neoplastic cells with exisulind results in growth inhibition and apoptosis.

In Vitro Results-- Topoisomerase I inhibitor Combination With cGMP PDE

Inhibitors

A. Procedure

Exisulind and Compound I were analyzed using two human lung cancer cell lines; H460, a large cell carcinoma with a doubling time of 16 hours, and Calu-6, an adenocarcinoma with a doubling time of 21 hours. Exisulind and Compound I were analyzed alone and in combination with the topoisomerase I inhibitor, Camptosar (irinotecan hydrochloride). The irinotecan was administered for 1 hour, while exisulind and Compound I were administered for either 1 hour or given as a continuous exposure.

Cells were plated on day 0 and allowed to attach. On day 1, the cells were exposed to irinotecan dissolved in media pre-warmed to 37°C and incubated at 37°C for 1 hour. The cells were then washed twice and re-fed pre-warmed media with or without either exisulind or Compound I and incubated for one hour at 37°C. After the one-hour incubation, the cells were washed twice, re-fed, and returned to the incubator; the continuous exposure cultures were not washed and re-fed. Appropriate controls were included for each condition. On day 4, after the cells had time to exhibit a response to the drug exposure, the cells were dissociated, counted, and the percent of control growth and standard deviations were calculated. All data points were done in triplicate and the mean graphed as a percent of control growth.

Exisulind and Compound I were first dissolved in DMSO and brought to the desired concentrations by slowly adding warm media to the drug-DMSO solution to prevent precipitation. The highest concentration of DMSO for the 1-hour exposures was 0.6%, which was also included in the 1-hour control, and resulted in no cytotoxicity compared to untreated controls.

B. Results

Compound I was approximately 80-100 fold stronger than exisulind in inhibiting cell growth in both cell lines (Figures 28-31). A continuous exposure to exisulind required approximately a 10 fold lower concentration than a 1-hour exposure to achieve the same effect (Figures 32-33). However, a continuous exposure to Compound I required a 25 fold lower concentration to achieve the same effect as a 1-hour exposure (Figures 28-29).

Exisulind and Compound I show an additive cytotoxic effect when combined with irinotecan (Figures 28-35) *in-vitro* and no antagonistic effects. For example, in Calu-6 cells a 1-hour exposure to 0.01 mcg/ml irinotecan resulted in 56% of control growth, a 1-hour exposure to exisulind (400 µg/ml) resulted in 54% of control growth, and the combination
5 resulted in 31% of control growth. Also in Calu-6 cells, a 1-hour exposure to 0.01 mcg/ml irinotecan resulted in 52% control of growth, a 1-hour exposure to 5 mcg/ml Compound I resulted in 47% of control growth, and the combination yielded 21% of control. This combined cytotoxic effect was seen in both cell lines for both Compound I and exisulind for both 1-hour and continuous exposures.

10 Dosage

The method of this invention involves using combination therapy to treat patients with neoplasia. Such combination therapy enhances the benefit to the patient without increasing harmful side effects. For example, exisulind is one cGMP-specific PDE inhibitor that can be used in combination with a topoisomerase I inhibitor in this invention.

15 Exisulind has no significant side effects when administered at its recommended dose of 300 - 600 mg/day. When administered at doses higher than the recommended therapeutic levels, treatment with exisulind can lead to elevated levels of liver enzymes. This effect is reversible, and liver enzymes return to normal levels when the administered dose of exisulind returns to the traditionally recommended level or when treatment is discontinued. The most
20 serious side effects of topoisomerase I inhibitor, on the other hand, are myelosuppressions. Since the side effects of the two drugs do not topoisomerase I inhibitor alkaloid derivative without increasing the harmful side effects of the topoisomerase I inhibitor.

A cGMP-specific PDE inhibitor and a topoisomerase I inhibitor can be used in combination in at least two different ways. In the first method, the traditionally
25 recommended dose range of the topoisomerase I inhibitor is reduced while its beneficial therapeutic effects are maintained and its side effects are attenuated. The second method uses the traditionally recommended dose range of the topoisomerase I inhibitor with enhanced activity but without increasing its side effects. In each of these methods, the patient is receiving both drugs, a PDE inhibitor and a topoisomerase I inhibitor, either simultaneously
30 or in succession.

The recommended dosage of a topoisomerase I inhibitor varies depending on the type of cancer being treated and whether the topoisomerase I inhibitor is being used in combination with another chemotherapeutic agent. In the practice of this invention, a cGMP-specific PDE inhibitor is used as an additional element of cancer treatment with a topoisomerase I inhibitor alone or with a group of chemotherapeutic agents.

The usual recommended starting dose of irinotecan injection is 125 mg/m^2 once a week. In patients with a combined history of prior pelvic/abdominal irradiation and modestly elevated serum total bilirubin levels (1.0 to 2.0 mg/dL) prior to treatment with irinotecan, there may be a substantially increased likelihood of grade 3 or 4 neutropenia. Consideration is often given to starting irinotecan at a lower dose (e.g., 100 mg/m^2 once a week) in such patients.

After initiation of treatment with irinotecan, patients should be carefully monitored for toxicity. Subsequent weekly doses should be adjusted to as high as 150 mg/m^2 or to as low as 50 mg/m^2 in 25 to 50 mg/m^2 increments depending upon individual patient tolerance of treatment.

Alternatively, irinotecan can be administered on a once-every-3-week dosage schedule. The usual recommended starting dose for the once-every-3-week dosage schedule is 350 mg/m^2 . For patients who are 70 years and older, or who have received prior pelvic/abdominal radiotherapy, or who have a performance status of 2 the recommended starting dose is 300 mg/m^2 . After initiation of treatment with irinotecan, patients should be carefully monitored for toxicity. Subsequent doses should be adjusted to as low as 200 mg/m^2 in 50-mg/m^2 increments depending upon individual patient tolerance of treatment.

Topotecan has been evaluated in cancer patients following doses of 0.5 to 1.5 mg/m^2 administered as a 30-minute infusion.

Rubitecan (from Supergen) also is an oral topoisomerase I inhibitor in the camptothecin class. It has been studied at doses of about $1.5 \text{ mg/m}^2/\text{day}$ for 5 days/week for 8 weeks.

In the practice of this invention, for each of the treatment methods mentioned above as well as other possible combinations, treatment with an appropriate cGMP-specific PDE inhibitor is added as an additional element of the therapy. A cGMP-specific PDE inhibitor and a topoisomerase I inhibitor are used in combination such that the blood levels of the inhibitor are at approximately the IC_{50} value of the inhibitor for growth inhibition. In the case of exisulind, it is recommended that the dose be about 200 to 400 mg/day administered between two to four times a day. In the case of Compound I, the dose is around 1000 mg/kg.

In one embodiment of this invention, the lower dose methodology, topoisomerase I inhibitor is administered at a dosage lower than the traditionally recommended dose for the indications above in each case, in combination with a cGMP-specific PDE inhibitor. Accordingly, the combination of therapies allows the benefits of antineoplastic topoisomerase I inhibitor treatment to be maintained while its side effects are reduced.

In the second embodiment, the dosage of topoisomerase I inhibitor is maintained at its traditionally recommended dose, and is administered in combination with a cGMP-specific PDE inhibitor.. The combination, in this case, increases the efficacy of topoisomerase I inhibitor treatment without increasing its harmful side effects.

In each of the aforementioned methodologies, the antineoplastic topoisomerase I inhibitor and the cGMP-specific PDE inhibitor may be administered simultaneously or in succession, one after the other.

Formulation

cGMP PDE-inhibiting compounds selected in accordance with the methodology of this invention may be formulated into pharmaceutical compositions as is well understood from the ordinary meaning of the term "pharmaceutical composition" i.e., a compound (e.g., like the solids described above) and a pharmaceutically acceptable carrier for delivery to a patient by oral administration in solid or liquid form, by IV or IP administration in liquid form, by topical administration in ointment form, or by rectal or topical administration in a suppository formulation. Carriers for oral administration are most preferred.

As is well known in the art pharmaceutically acceptable carriers in pharmaceutical compositions for oral administration include capsules, tablets, pills, powders, troches and granules. In such solid dosage forms, the carrier can comprise at least one inert diluent such as sucrose, lactose or starch. Such carriers can also comprise, as is normal practice,

additional substances other than diluents, *e.g.*, lubricating agents such as magnesium stearate. In the case of capsules, tablets, troches and pills, the carriers may also comprise buffering agents. Carriers such as tablets, pills and granules can be prepared with enteric coatings on the surfaces of the tablets, pills or granules. Alternatively, the enterically-coated compound
5 can be pressed into a tablet, pill, or granule, and the tablet, pill or granules for administration to the patient. Preferred enteric coatings include those that dissolve or disintegrate at colonic pH such as shellac or Eudraget S.

Pharmaceutically acceptable carriers in pharmaceutical compositions include liquid dosage forms for oral administration, *e.g.*, pharmaceutically acceptable emulsions, solutions,
10 suspensions, syrups and elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.

Pharmaceutically acceptable carriers in pharmaceutical compositions for IV or IP administration include common pharmaceutical saline solutions.

15 Pharmaceutically acceptable carriers in pharmaceutical compositions for topical administration include DMSO, alcohol or propylene glycol and the like that can be employed with patches or other liquid-retaining material to hold the medicament in place on the skin so that the medicament will not dry out.

Pharmaceutically acceptable carriers in pharmaceutical compositions for rectal
20 administration are preferably suppositories that may contain, in addition to the compounds of this invention excipients such as cocoa butter or a suppository wax, or gel.

A pharmaceutically acceptable carrier and compounds of this invention are formulated into pharmaceutical compositions in unit dosage forms for administration to a patient. The dosage levels of active ingredient (*i.e.*, compounds selected in accordance with
25 this invention) in the unit dosage may be varied so as to obtain an amount of active ingredient effective to achieve neoplasia-eliminating activity in accordance with the desired method of administration (*i.e.*, oral or rectal). The selected dosage level therefore depends upon the nature of the active compound administered (*e.g.*, its IC_{50} , which can be readily ascertained), the route of administration, the desired duration of treatment, and other factors. If desired,
30 the unit dosage may be such that the daily requirement for active compound is in one dose, or divided among multiple doses for administration, *e.g.*, two to four times per day.

For IV administration, an initial dose for administration can be ascertained by basing it on the dose that achieves a plasma concentration similar to the *in vitro* neoplastic cell growth inhibition IC₅₀. Since the average adult male has about 4 liters of plasma, initial doses of active compound selected in accordance with this invention can range from 0.5-600 mg.

Packaging

As indicated above, the pharmaceutical compositions of this invention are preferably packaged in a container (*e.g.*, a box or bottle, or both) with suitable printed material (*e.g.*, a package insert) containing indications, directions for use, etc. To draw the association between this novel pathway and the pharmaceutical, one skilled in the art does not necessarily have to be advised about each and every aspect of the pathway. At some time, one skilled in the art, for example, will come to understand the characteristics of these compound, so it may suffice to inform that person that a compound in question is an anti-neoplastic PDE5 inhibitor, without reference to the companion or down-stream effects of that inhibition. One skilled in the art will readily come to recognize that the pathway disclosed herein involves its various individual components, so ultimately to refer to any one of those components in connection with a pharmaceutical composition may suffice to inform physicians and/or patients that that composition acts through this pathway and induce patients to use that composition.

In addition to being useful to physicians and patients, the fact that a pharmaceutical composition has an active ingredient that acts through this pathway may be useful in obtaining regulatory approval for that pharmaceutical composition. As explained above, regulatory approval in the U.S. Food and Drug Administration involves two questions: whether the drug is effective and whether it is safe (at least when weighed against the clinical benefit the drug may provide). By operating through the novel pathway disclosed herein, a pharmaceutical composition can be demonstrated to be effective, as the results presented above demonstrate. Once regulatory authorities come to understand that one drug is effective through this pathway, the next drug will raise fewer questions about efficacy.

Equally if not more significant is the regulatory advantage in operating through this clinically safe pathway to inhibit neoplasia. Pharmaceutical development of anti-neoplastics has a prior history of drugs being effective against neoplasia but being refused regulatory

approval because of safety issues. In addition, prior history has examples of where regulatory authorities have recommended restrictions on usage or narrowed indications of an anti-neoplastic for safety reasons that limit a wider use of the drug. With the safety profile of compounds such as those above that act through the pathway disclosed herein, provided such a drug is effective, the safety profile is one that will not likely lead to non-approval or argue for restrictions on use if approved. Thus, when one assembles and submits documents (e.g., integrated summaries of safety and efficacy, and final study reports and associated locked databases well known in the regulatory arts) for approval of such pharmaceutical compositions, there is a definite regulatory advantage in seeking regulatory approval for an anti-neoplastic drug fitting the profile described herein, as opposed to an anti-neoplastic that does not. Hence, another aspect of this invention is a process for improving the approvability of an anti-neoplastic pharmaceutical composition that involves developing a compound having the characteristics described above, formulating it into a pharmaceutical composition, and submitting that composition for regulatory approval after having performed the necessary clinical studies that are well known in the art.

Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.

20

WE CLAIM:

1. A composition comprising a topoisomerase I inhibitor and an inhibitor of a cGMP specific phosphodiesterase inhibitor for use as a medicament.
2. A composition according to claim 1 wherein said inhibitor also inhibits PDE2.
- 5 3. A composition according to claim 1 wherein said inhibitor comprises exisulind.
4. A method of inhibiting the growth of neoplastic lesions in a patient comprising administering to the patient a topoisomerase I inhibitor and a cGMP-specific phosphodiesterase inhibitor.
- 10 5. The method of claim 4 wherein the topoisomerase I inhibitor is administered simultaneously with the cGMP-specific phosphodiesterase inhibitor.
6. The method of claim 4 wherein the topoisomerase I inhibitor is administered alternately with the cGMP-specific phosphodiesterase inhibitor.
7. The method of claim 4 wherein the topoisomerase I inhibitor is irinotecan
15 which is administered at a dosage of at least 100 mg/m².
8. The method of claim 4 wherein the topoisomerase I inhibitor is irinotecan which is administered at a dosage less than about 100 mg/m².
9. The method of claim 4 wherein the topoisomerase I inhibitor is topotecan which is administered at a dosage of about between 0.5 and 1.5 mg/m².
- 20 10. The method of claim 4 wherein the topoisomerase I inhibitor is topotecan which is administered at a dosage less than about 0.5 mg/m².
11. The method of claim 4 wherein the topoisomerase I inhibitor is rubitecan which is administered at a dosage of about 1.5 mg/m².
12. The method of claim 4 wherein the topoisomerase I inhibitor is rubitecan
25 which is administered at a dosage less than about 1.5 mg/m².
13. A kit comprising a topoisomerase I inhibitor and an inhibitor of a cGMP-specific phosphodiesterase for simultaneous or sequential administration to a patient to treat neoplastic lesions.
14. A packaged pharmaceutical composition for the treatment of neoplasia,
30 comprising:

- 5
- (a) a pharmaceutical composition containing a pharmaceutically acceptable carrier and a topoisomerase I inhibitor;
 - (b) written material describing said compound and providing directions for use with an anti-neoplastic cGMP PDE inhibitor; and
 - (c) packaging for carrying said pharmaceutical composition and said written material.

15. A packaged pharmaceutical composition for the treatment of neoplasia, comprising:

- 10
- (a) a pharmaceutical composition containing a pharmaceutically acceptable carrier and an anti-neoplastic cGMP PDE inhibitor;
 - (b) written material describing said compound and providing directions for use with an a topoisomerase I inhibitor; and
 - (c) packaging for carrying said pharmaceutical composition and said written material.

15

1/28




FIGURE 1




FIGURE 2

2/28

Kinetic behavior of peak B:
cGMP positive cooperative
activation of cGMP hydrolysis




FIGURE 3

3/28




FIG. 4




FIG. 5

5/28







FIG. 6

6/28

**FIG. 7A****FIG. 7B**

7/28

**FIG. 8**

8/28








FIG. 9


9/28


**FIG. 10A****FIG. 10B**



10/28



**FIG. 11A****FIG. 11B**


11/28

**FIG. 12**


**FIG. 13**

**FIG. 14****FIG. 17**

**FIG. 15A**

**FIG. 16**

16/28

**Figs. 18A and 18B****Protein kinase G activity from drug-treated SW480 cell lysates.**

SW480 cells were treated with DMSO (0.03%, lanes 1 and 2), Exisulind (200, 400 and 600 μ M; lanes 3, 4, 5, respectively) and E4021 (0.1, 1 and 10 μ M, lanes 6, 7, 8, respectively) for 48 hrs.




Figure 19

18/28




Figure 20

19/28




Figure 21




Figure 22

21/28

DEAE Trisacryl M
Chromatography of LnCAP,
Low vs. High substrate





Figure 23

22/28



*The bound H³-cGMP was determined by incubating of 2 μ M H³-cGMP with the analogs (100 μ M) and purified soluble GST-cGB-PDE5 (30 μ g) at 22°C for 1 hour.

Figure 24

23/28




FIGURE 25

24/28




FIGURE 26

25/28

Figure 28
Calu-6 Cells (Compound I – 1 Hour Exposure)





Figure 29
Calu-6 Cells (Compound I – Continuous Exposure)



26/28

Figure 30
H460 Cells (Compound I – 1 Hour Exposure)





Figure 31
H460 Cells (Compound I – Continuous Exposure)



27/28

Figure 32
Calu-6 Cells (Exisulind – 1 Hour Exposure)





Figure 33
Calu-6 Cells (Exisulind – Continuous Exposure)



28/28

Figure 34
H460 Cells (Exisulind – 1 Hour Exposure)





Figure 35
H460 Cells (Exisulind – Continuous Exposure)



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 October 2001 (25.10.2001)

PCT

(10) International Publication Number
WO 01/78651 A3

- (51) International Patent Classification⁷: **A61K 31/19**, 31/44
- (21) International Application Number: PCT/US01/11865
- (22) International Filing Date: 12 April 2001 (12.04.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/548,135 12 April 2000 (12.04.2000) US
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant: **CELL PATHWAYS, INC.** [US/US]; 702 Electronic Drive, Horsham, PA 19044 (US).
- Published:
— with international search report
- (72) Inventors: **PAMUKCU, Rifat**; 2 Pump House Drive, Spring House, PA 19477 (US). **LOBACKI, Joseph**; 1263 Turnbury Lane, North Wales, PA 19454 (US).
- (88) Date of publication of the international search report:
14 March 2002
- (74) Agent: **STEVENSON, Robert, W.**; Cell Pathways, Inc., 702 Electronic Drive, Horsham, PA 19044 (US).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/78651 A3

(54) Title: METHOD FOR TREATING NEOPLASMIN WITH TOPOISOMASE I INHIBITOR

(57) Abstract: This invention provides a method for treating a patient with neoplasia by an adjuvant therapy that includes treatment with a topoisomerase I inhibitor.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/11665

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 31/19, 31/44 US CL : 514/283, 569 According to International Patent Classification (IPC) or to both national classification and IPC																										
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/283, 569 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)																										
C. DOCUMENTS CONSIDERED TO BE RELEVANT																										
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																								
Y	WO 99/49859 A1 (THE ARIZONA BOARD OF REGENTS) 07 October 1999 (07.10.99), see entire document.	1-15																								
Y	STN DATABASE Chem. Abstr., Columbus, OH, USA AN 1998:677659, ARBUCK et al., An Overview of Topoisomerase I-targeting Agents (1998) SEMIN. HEMATOL. Vol. 35, No. 3, Suppl. 4, pp. 3-12.	1-15																								
A	US 6,200,771 B1 (LIU et al.) 13 March 2001 (13.03.01), see entire document.	1-15																								
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																										
<table border="0"> <tr> <td colspan="2">* Special categories of cited documents:</td> <td>*T</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*E</td> <td>earlier document published on or after the international filing date</td> <td>*Y</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*Z</td> <td>document member of the same patent family</td> </tr> <tr> <td>*O</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>*P</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:		*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A	document defining the general state of the art which is not considered to be of particular relevance	*X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E	earlier document published on or after the international filing date	*Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z	document member of the same patent family	*O	document referring to an oral disclosure, use, exhibition or other means			*P	document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:		*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																							
*A	document defining the general state of the art which is not considered to be of particular relevance	*X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																							
*E	earlier document published on or after the international filing date	*Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																							
*L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z	document member of the same patent family																							
*O	document referring to an oral disclosure, use, exhibition or other means																									
*P	document published prior to the international filing date but later than the priority date claimed																									
Date of the actual completion of the international search 04 AUGUST 2001		Date of mailing of the international search report 19 DEC 2001																								
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer JEROME D. GOLDBERG Telephone No. (703) 308-1235																								